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Abstract  
 
Green tea is widely consumed worldwide, second only to water. Its 
health effects have been attributed to its polyphenolic catechin content, 
which accounts for a significant percentage of its dry weight. 
Epidemiological studies have observed beneficial health effects of green 
tea catechins against some cancers, cardiovascular diseases, and 
neurodegenerative diseases. However most studies have also been 
carried out in vitro where the concentrations of catechins used are not 
obtainable in the human body. The in vivo situation is very complicated 
and relies on favourable absorption, metabolism, and excretion of the 
catechins. In this thesis it is reported, the potential health benefits of 
green tea catechins in tissues which are highly and most often in contact 
with catechins, the oral cavity and the intestine. In experiments 
modelling the oral cavity the four major catechins were extensively 
absorbed into H400 cells, and showed significant protection at 
physiological concentrations against H2O2 induced mitochondrial DNA 
damage. Thereafter the in vitro metabolism of catechins were measured 
using various intestinal and liver enzyme fractions. It was shown, that in 
these systems, glucuronidation was the main metabolism pathway. 
These enzyme fractions also provided mixtures of metabolites which 
were used to measure their comparative bioactivities in relation to their 
parent compounds. This was done via the assessment of their protective 
effects against H2O2 induced mtDNA damage in human intestinal cells. 
The metabolites were shown to be significantly bioactive; however the 
majority of the metabolites had lower bioactivities than the parent 
compound. In the final study the aim was to inhibit the glucuronidation of 
catechins to aid in the development of strategies to enhance catechin 
bioavailability. The two compounds chosen have previously been shown 
to inhibit intestinal glucuronidation. In this study it was determined that 
both piperine and quercetin significantly inhibited the metabolism of the 
catechins in intestinal microsomes. These studies taken together give a 
platform for future studies to be carried out which will be more detailed 
and rigorous.  
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Chapter 1 – Introduction 
 
 
1.1 - Sources, dietary abundance and intake of flavonoids 
 
Flavonoids are a group of polyphenolic compounds widely distributed in 
nature, mainly in plant foods, and contain two or more aromatic rings 
(Heim et al., 2002, Harborne and Williams, 2000).  These compounds 
have roles in flavour, pigmentation and plant physiology, and have been of 
great interest for the last two decades for their potential health benefits 
owing to their  radical oxygen species (ROS) scavenging abilities 
(Iwashina, 2000). There is a lack of uniform distribution in the amount of 
flavonoids present in different plants; for example soy flour can contain 
800 - 1800 mg/kg isoflavones, whereas tomatoes can contain as little as 2 
– 15 mg/kg flavonols (Hertog et al., 1992, Franke et al., 1999, Coward et 
al., 1993). The richest sources of flavonols are onions (can be up to 1.2 
g/kg), with considerable amounts also found in broccoli, blueberries, leeks, 
kale, tea, and red wine (Justesen et al., 1998, Herrmann, 1976, Hertog et 
al., 1993b, Crozier et al., 1997). These flavonols are generally present in 
the diet in their glycoside forms, with rhamnose or glucose being the most 
common sugar moiety (Veitch and Grayer, 2008). Polyphenol intake 
amongst the general population can reach up to 1 g/day in individuals who 
consume many portions of fruit and vegetables and varies dramatically 
based on the types of flavonoids and the populations studied (Erlund et al., 
2002, Scalbert and Williamson, 2000). In Denmark, Holland, and the 
United States, flavonol consumption has been estimated at between 20 – 
25 mg/day (Sampson et al., 2002, Justesen et al., 1997, Hertog et al., 
1993a). Anthocyanins are consumed on average at 82 mg/day in 
populations who consume high amounts of berries and could exceed 200 
mg/day (Mursu et al., 2008).  
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1.2 - Bioavailability of Flavonoids 
 
Bioavailability has been defined by the US food and drug administration as 
“the rate and extent to which the active ingredient or active moiety is 
absorbed from a drug product and becomes available at the site of action” 
(Food and Drug Administration. Code of federal regulations, 2012).  
Polyphenols that are present in the diet at higher amounts do not 
necessarily have better bioavailability then polyphenols present in lower 
amounts; this is due to bioavailability-affecting factors, which include 
intestinal transit time, food matrix, colonic and phase II metabolism, 
chemical structure of the flavonoid, genetics, interactions with other 
compounds, absorption, and methods of consumption (Williamson and 
Manach, 2005, Manach et al., 2004, Schramm et al., 2003, Roura et al., 
2007, Passamonti et al., 2002, Azuma et al., 2002).  
Flavonoids undergo extensive UDP-glucuronosyl transferase, catechol-O-
methyl transferase, and sulfotransferase mediated phase II metabolism 
before being passed into the circulation; forming methylated, sulfated, or 
glucuronide metabolites. The ATP-binding cassette (ABC) transporter 
family, which includes the P-glycoproteins (P-gp) and the multidrug 
resistance proteins (MRP), mediate the ATP dependent efflux of flavonoid 
metabolites back into the lumen of the intestine (Walle et al., 1999, 
Walgren et al., 2000, Hu et al., 2003). These factors taken together can 
severely limit the bioavailability of flavonoids and explain their generally 
low bioavailability.  
 
1.3 - Bioactivity of flavonoids and their metabolites 
 
Flavonoids are known to be extensively conjugated upon ingestion, 
Therefore, the bioactivity of flavonoids can at least in part, be attributed to 
their circulating metabolites. This applies to the anthocyanins. After 
ingestion, 60 – 90 % of Anthocyanins are rapidly degraded or metabolised, 
with approximately 72 % accounted for by the major metabolite; 
protocatechuic acid (Galvano et al., 2008). Upon metabolism, the structure 
of the compound is changed and the bioactivity may be altered. Generally 
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the bioactivity is thought to be reduced as metabolism typically inactivates 
ingested compounds and effectively marks them for excretion via the urine 
or bile (Tukey and Strassburg, 2000, Lu et al., 2003a). These metabolites 
can also be just as biologically potent as the parent compounds or 
sometimes even more biologically active, as is the case with morphine 
glucuronides (Paul et al., 1989). The effect of bioactivity can also depend 
on the site of conjugation. EGCG glucuronides at the 3’ and 3’’ positions 
had the same radical scavenging capability as EGCG, whereas the 
glucuronides at positions 7 and 4’’ were less bioactive when comparing 
radical scavenging capacity (Lu et al., 2003). Most studies show that 
flavonoid metabolites do have lower bioactivities than their parent 
compounds (Delgado et al., 2014, Lambert et al., 2007). Most studies use 
deconjugated or parent compounds in bioactivity studies, not taking into 
account that many of the bioactivities could be due the metabolites. 
However, recently this has received more attention, owing to the 
realisation that most circulating forms of flavonoids in the plasma are 
conjugated (Renouf et al., 2011, Pietta et al., 1998, Meng et al., 2001, 
Mullen et al., 2004, Clifford et al., 2013).  
 
1.4 - Summary 
 
Polyphenols are consumed in high amounts by individuals who have high 
plant-based diets. A significant number of studies have been carried out 
over the last two decades that have correlated health effects with the 
intake of dietary polyphenols. These studies have also elucidated the 
metabolism and bioavailability of these flavonoids to a reasonable extent, 
which can further be interpreted as contributing to the benefits on human 
health (Williamson and Manach, 2005, Scalbert and Williamson, 2000). 
Although some mechanisms of flavonoids acting on cells have been better 
understood recently, much more rigorous and detailed studies are needed 
to find exact mechanisms of action and cellular targets. Most studies on 
mechanisms of action are carried out in vitro, using concentrations that are 
unachievable in the circulation and parent compounds which do not 
necessarily reflect the conjugated forms found in plasma, so it’s imperative 
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to interpret these results carefully. The polyphenols should also be able to 
reach the target tissues/organs which are being studied and correlated 
with potential beneficial health effects. For example there is no point 
studying the effects of certain polyphenols on neurons in vitro if that 
particular flavonoid cannot cross the blood-brain barrier in vivo. Exceptions 
of course would be the study of polyphenols on intestinal cells, as they are 
directly in contact with ingested flavonoids in the GI tract. In studies of 
polyphenol health effects, especially in epidemiological studies, data have 
proven inconclusive regarding health effects in humans, and therefore are 
insufficient to claim outright positive effects of polyphenol consumption. 
Further research is required for the exact ADME properties of flavonoids to 
help elucidate exactly which metabolites contribute to certain health 
effects. 
 
 
1.5 - Structure of thesis and aims 
 
The thesis is organised into 7 chapters; a small general introduction to 
polyphenols and flavonoids, literature review, four chapters on 
experimental work, and a general discussion and conclusions chapter.  
There are currently no data in the literature regarding the absorption or 
uptake of green tea catechins in the oral mucosa and if there are any 
metabolites produced after absorption in the oral cavity. The aim of work 
presented in chapter 3 was to elucidate the absorption of green tea 
catechins in human oral cells, potential formation of metabolites, and the 
protective effects of those catechins against H2O2 induced mitochondrial 
DNA damage in the oral cavity.  
Extensive studies on the metabolism of catechins have been carried out 
previously (Zhu et al., 2000, Vaidyanathan and Walle, 2002, Vaidyanathan 
and Walle, 2001, Spencer, 2003, Okushio et al., 1999, Lu et al., 2003b, Lu 
et al., 2003a). However what is lacking in these studies is data on the 
formation of catechin metabolites at regular time-points over a 
physiological time range which reflects the average length of transit 
through the GI tract in humans. Therefore the aim in chapter 4 was to 
analyse the metabolism of green tea catechins in different enzyme 
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fractions of intestine and liver, and catechol-O-methyl transferase from 
porcine liver. As the formation of metabolites of green tea catechins over 3 
hours has not been previously reported, it was analysed at various time-
points from 0 to 180 minutes.  
Mitochondria are the main site of reactive oxygen species (ROS) 
production in the cell. The close proximity of mitochondrial DNA to these 
may make it more susceptible to ROS induced damage (Alexeyev, 2009). 
In chapter 5, it is hypothesised that green tea catechins and their 
metabolites (purified metabolites, and metabolite mixtures formed from 
enzyme assays in chapter 4) would protect mitochondrial DNA from 
damage in intestinal cell lines.  
 
As the bioavailability of catechins is very low, chapter 6 looks at strategies 
to decrease metabolism of catechins in vitro for the potential application to 
in vivo studies to help increase bioavailability. Two dietary inhibitors of 
intestinal glucuronidation (piperine and quercetin) have been identified 
(Lambert et al., 2004, Mohamed and Frye, 2010) and it was hypothesised 
that catechin glucuronidation by intestinal microsomes would be 
decreased in the presence of these compounds. Chapter 7 contains 
general discussion and conclusions, and possible future directions. 
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Chapter 2 - Literature review: green tea catechins  
 
After water, tea is the most largely consumed beverage worldwide, 
estimated at 120 ml/day per capita consumption. Its popularity is attributed 
to its flavour, proposed health benefits, and its characteristic aroma. From 
the leaves of the plant Camellia sinensis there are approximately 300 
different types of tea manufactured using various processing methods. 
However, there are three major commercial varieties of tea available: 
green (20% consumption), oolong (2% consumption), and black tea (78% 
consumption). Black tea is largely consumed in Europe and the USA, 
whereas in Asia green tea is most commonly consumed (Balentine et al., 
1997, Katiyar and Mukhtar, 1996).  
The various forms of tea are prepared from an infusion of plant leaves 
from the plant Camellia sinensis, which is today produced in over 30 
countries worldwide, and for thousands of years has been cultivated in 
Asia. Each year approximately 2.5 million metric tonnes of tea are 
produced, which go through different processes of enzymatic oxidation or 
fermentation to make black tea, green tea, or oolong tea. These different 
processes give rise to varying chemical compositions (Matthew E. 
Harbowy, 1997).    
Tea leaves are fully fermented to produce black tea, where the enzyme 
polyphenol oxidase (Kumar et al.) found in the plant, oxidises catechins 
present in the tea leaves to theaflavins and thearubigins. Green tea 
production involves the inactivation of the PPO enzyme and is prepared by 
steaming and drying the tea leaves, thus maintaining the catechins 
present in the tea leaves. Oolong tea undergoes partial fermentation, and 
ends up with chemical composition that is in between that of black and 
green tea (Balentine et al., 1997, Matthew E. Harbowy, 1997). 
Green tea has been extensively studied for potential health beneficial 
effects, including prevention of cancer, heart disease, diabetes, and 
neurodegenerative diseases (Lambert et al., 2005, Yang et al., 2006, 
Higdon and Frei, 2003, Weisburger, 1999). The health benefits of tea are 
generally ascribed to its polyphenol content; the major polyphenols in 
green tea being catechins which are categorised by a di- or tri-hydroxyl 
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group substitution of the B ring and the meta-5,7-dihydroxyl substitution of 
the A ring (figure 1). 
 
                      
  Figure 1 - Chemical structures of the four major Catechins  
 
The average cup of brewed green tea has 30-40% catechins (dry weight), 
including: catechin (C), epicatechin (EC), epigallocatechin (EGC), 
epicatechin-3-gallate (ECG), and epigallocatechin-3-gallate (EGCG) 
(Balentine et al., 1997). EGCG is the most abundant (50-80% of total 
catechin content) and widely studied (Balentine et al., 1997, Graham, 
1992).Green tea catechins have been shown to have potential beneficial 
health effects in studies of Parkinson’s disease (Choi et al., 2002), 
Alzheimer’s disease (Obregon et al., 2006, Ramassamy, 2006), stroke 
(Choi et al., 2004, Koh et al., 2006), obesity (Lin and Lin-Shiau, 2006), 
diabetes (Anderson and Polansky, 2002), and chemoprevention (Adhami 
et al., 2007, Clark and You, 2006, Kumar et al., 2007). Their high 
antioxidant activity makes them very efficient scavengers of peroxynitrite, 
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singlet oxygen, superoxide, and nitric oxide (Guo et al., 1999, Lambert and 
Elias, 2010). They also have potential as anti-inflammatory agents (Ahmed 
et al., 2006, Tedeschi et al., 2002), iron & copper ion chelators (Wang et 
al., 2007), antioxidant and other detoxifying enzyme upregulators (Khan et 
al., 1992, Chou et al., 2000), and in protection of DNA against oxidative 
damage (Luo et al., 2006). 
 
Although catechins have long been characterized as powerful antioxidants 
in vitro, evidence suggests that these compounds undergo significant 
metabolism in the liver, small intestine, and colon. Biotransformation of 
catechins leads to the formation of glucuronide and sulfate conjugates, 
and methylated metabolites. Significant biotransformation of green tea 
catechins occurs in the colon where the resident microflora degrades them 
to small phenolic acids, some of which may be absorbed (Lu et al., 2003b, 
Vaidyanathan and Walle, 2002, Crespy et al., 2004, Lu et al., 2003a, 
Feng, 2006, Spencer, 2003, Zhu et al., 2000). It has been realised that 
very low bioavailability and extensive metabolism of green tea polyphenols 
in humans and animals reduces biological activity substantially (Manach et 
al., 2005, Williamson and Manach, 2005, Hollman et al., 1997).  
 
2.1 Bioavailability of Catechins 
 
Biological properties of polyphenols depend on their bioavailability. After 
ingestion, the metabolism of polyphenols should be carefully studied, since 
it is obvious that polyphenols should be bioavailable in some form or other 
to exert biological effects. There have been significant advances in our 
knowledge of polyphenol absorption and metabolism in the past few years, 
and it is evident that some classes of polyphenols (Isoflavones among 
others) are sufficiently absorbed to have the potential to exert biological 
effects (Hollman et al., 1997). One of the main objectives of bioavailability 
studies is to determine, among the hundreds of dietary polyphenols, which 
are better absorbed and which lead to the formation of active metabolites 
(D’Archivio et al., 2010). In most cases this is not done in a comparative 
way, as bioactivity depends on more than just bioavailability. There are 
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countless studies on the effects of polyphenols on biological systems in 
vitro, such as intestinal and hepatic  cancer cell lines, but many of them 
have not taken bioavailability and metabolism factors into consideration, 
and the effects reported in these studies do not necessarily occur in vivo. 
Although most polyphenols are absorbed to some extent, this is usually 
also dependent on the type of polyphenol (Manach et al., 2005).  
The range of concentrations required for an effect in vitro varies from 0.1 
μM – 100 μM. However, physiological plasma concentrations do not 
exceed 10 μM (high end of plasma concentration range), hence the effects 
of polyphenols in vitro at concentrations of >10 μmol/L are generally not 
representative of the situation occurring in vivo (Manach et al., 2005, Kidd, 
2009, D’Archivio et al., 2010). In the case of catechins plasma 
concentrations rarely exceed 1 μM, and bioavailability studies of catechins 
are not usually consistent in their findings (Yang et al., 1999, Wiseman et 
al., 2001, Williamson and Manach, 2005, Lee et al., 2002, Henning et al., 
2004). Furthermore, absorption is accompanied by extensive conjugation 
and metabolism, and the forms appearing in the plasma are usually 
different from the forms found in the food/beverage; e.g. the compound 
EGC in the beverage, is found mainly in the plasma as glucuronide and 
sulphate conjugates (Lee et al., 1995). This can lead to confounded 
attempts to compare in vitro findings with in vivo results in humans and 
animal models.  
Some studies have investigated the kinetics and extent of polyphenol 
absorption and/or metabolism by measuring plasma concentrations and 
urinary excretion in humans after the ingestion of a single dose of 
polyphenol, provided as a pure compound, plant extract, or whole 
beverage (Hollman et al., 1997, Pietta et al., 1998, Harada et al., 1999, 
Chan et al., 2007, Hong et al., 2003, Hu et al., 2003, Renouf et al., 2011, 
Hong et al., 2002, Stalmach et al., 2009).  
The daily consumption of catechins is estimated to be approximately 18–
50 mg/d, with the main sources being tea, chocolate, apples, pears, 
grapes, and red wine. Although they are present in many foods and 
beverages, the bioavailability of catechins has been studied mainly after 
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the intake of green tea and cocoa (Arts et al., 2000, Williamson and 
Manach, 2005). Among catechins, bioavailability varies distinctly (Table 1).  
The bioavailability of green tea catechins is mainly determined via the 
analysis of biological fluids such as plasma and urine at various time-
points after the consumption of green tea, catechins in a capsule, or green 
tea extract form (Del Rio et al., 2010, Henning et al., 2004, Stalmach et al., 
2009). It is virtually impossible to accurately determine bioavailability of 
green tea catechins in humans, as ideally the bioavailability would be 
measured by comparison of the plasma concentrations of the non-
conjugated catechins after oral and IV administration of the same dose. 
Also it would be helpful to analyse the concentrations of catechins and 
their metabolites in certain target organs, but due to the difficulty in 
accessing the organs in humans, studies on animals are conducted. The 
disadvantage to this is that the metabolism and bioavailability may vary 
significantly between animals and humans, further adding difficulty to 
accurate determinations of bioavailability in humans. 
As already indicated, the favourable health effects of tea catechins are 
essentially associated to their bioavailability, absorption, distribution, 
metabolism, and excretion from the body (Figure 2). Catechins are quite 
high molecular weight compounds (300-450 Da) consisting of more than 5 
hydroxyl groups, and according to Lipinski’s rule of five, they should have 
low bioavailability due to their large size (Lipinski et al., 2001). When 
consumed in representative amounts of 1-2 cups/100-200 mg of 
catechins, the level of catechins and other flavonoids in plasma does not 
exceed 1 μM. The overall plasma concentration of catechins (conjugated 
and free) is approximately 2-3 μM, or less (Yang et al., 1998), (Warden et 
al., 2001).  
Approximately 1-2 hours after tea consumption, the concentration of 
catechins in human plasma increases. However, the bioavailability of 
catechins is rather low — only 0.2–2 % of the consumed amount of 
catechins gets into plasma of healthy humans, in parent and conjugate 
forms (Wiseman et al., 2001). 
The bioavailability of pure EGC, ECG, and EGCG in healthy volunteers 
was investigated. After consumption of 1.5 mM EGC, ECG, and EGCG 
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alone, the mean plasma concentration was 5 μМ, 3.1 μМ, and 1.3 μМ 
respectively (van het Hof et al., 1998). These plasma concentrations are at 
the upper limit of concentrations obtained, and are not achievable by 
drinking green tea without supplementation with pure catechins.  
After oral consumption of 100 to 1600 mg of pure EGCG, 0.26 to 6.35 μM 
of EGCG was detected in plasma in 2-3 hours; some metabolites of EGCG 
at concentrations of 0.28 to 7.40 μM were also found between 1.9 - 4.6 
hours (Ullmann et al., 2003). Again, these high plasma concentrations are 
only found after ingestion of very high doses of pure catechins, and cannot 
be achieved after consumption of reasonable amounts of green tea alone. 
To ingest up to 1600 mg of EGCG from green tea, one would have to drink 
between 8 – 16 cups per day.  
Del Rio et al studied the bioavailability of GTCs after the consumption of 
tea, and the urine of volunteers was analysed over 24 hours (Del Rio et 
al., 2010). Eight catechin metabolites and unconjugated gallic acid were 
identified in urine. Urine contained 7.2% of GTCs and 4.5% of gallic acid in 
relation to their total amounts contained in the consumed tea. The Cmax of 
5 metabolites (methyl-epigallocatechin glucuronide, epigallocatechin 
glucuronide, methyl-epicatechin sulfate, epicatechin sulfate, and 
epicatechin glucuronide) were observed in the urine 4 hours after 
consumption of the tea; the Cmax level of 2 metabolites (methyl-
epigallocatechin sulfate and methyl-epigallocatechin) were present in the 
urine after 10 hours; whereas the content of epigallocatechin in the urine 
was seen as continuously increasing over the period of 24 hours. A 
previous study by Stalmach et al showed similar  bioavailability to this 
study (Stalmach et al., 2009). Absorption, metabolism, and excretion in 
urine of GTCs were studied by HPLC-MS in 10 healthy volunteers who 
were taking 500 ml of Choladi green tea, containing 648 μM of flavan-3-ols 
(Stalmach et al., 2009). After consumption of green tea, plasma and urine 
were analysed over 24 hours. Ten methylated, sulfated, and glucuronide 
metabolites of EC and EGC at a concentration of 29-126 nM were found to 
occur 1.6-2.3 hours after consumption. This indicates that absorption 
occurs in the small intestine. Plasma also contained unconjugated EGCG 
and ECG at concentrations of 55 and 25 nM, respectively. Fifteen 
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metabolites of EC and EGC were identified in urine. No metabolites of 
EGCG and ECG were detected. Overall green tea catechin excretion was 
estimated at 8.1% of intake but excretion of certain flavanols varied from 
11.4% to 28.5% of intake. These studies show that epicatechins are more 
bioavailable than other catechins in green tea. 
The data shows that bioavailability of the different catechins varies 
significantly in different studies. It is estimated that at any one time, 80% of 
green tea catechins are in the urine and plasma in their conjugated forms, 
which can still scavenge superoxide free radicals, as some metabolites 
retain their intact hydroxyl substituents (Kuhnle et al., 2000, Vaidyanathan 
and Walle, 2002, Li et al., 2001, Li et al., 2000). The doses of GTCs, 
populations, and matrices of delivery used in bioavailability studies are 
usually not kept constant, which could give one explanation for the 
inconsistencies in the data obtained in different bioavailability studies. 
Another inconsistency is the differences in methodologies used to quantify 
and analyse GTCs in biological fluids.  
 
 
Figure 2. The pathways taken by catechins through the enterocyte. Absorption (1), 
intracellular metabolism (2), conjugation (3), and efflux across membrane (4). 
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Source 
Dose 
(mg) Tmax (h) 
Plasma conc 
μmol/L Half-life (h) Reference 
Pure 
EGCG 
50-1600 1.3–2.2 0.28- 7.4  1.9–4.6 
(Ullmann et al., 
2003) 
 200-800 1.8–4 0.16-0.96 1.9–3.1 (Chow et al., 2001) 
Polypheno
n E 
200-800  2.4–4.1 0.16-0.82 (EGCG) 1.9–3 (Chow et al., 2001) 
 164 (TC’s) - 0.56 TC’s at 3 h - 
(van het Hof et al., 
1998) 
Green tea 
powder 
105 
EGCG 
2.0 0.14–0.31 EGCG - (Unno et al., 1996) 
Pure ECG 663 4.0 3.1 ECG 6.9 
(Van Amelsvoort et 
al., 2001) 
Green tea 
extract 
225-525 
EGCG 
7.5-17.5 
EGC  
0.66-4.4 EGCG at 
1.5h 
0.03-0.25 EGC at 
1.5h - 
(Nakagawa et al., 
1997) 
(Nakagawa et al., 
1997) 
 88 EGCG - 0.24 EGCG at 1 h - (Yang et al., 1998) 
 82 EGC - 0.46 EGC at 1 h 2.0 TC’s (Yang et al., 1998) 
 109.5-328 
EGCG 
1.6- 2.7 0.26-0.70 EGCG 4.9-5.5 
(Kimura et al., 
2002) 
 102-306 
EGC 
1.3-1.8 0.48-1.8 EGC 2.5- 2.8 
(Kimura et al., 
2002) 
 37.5-112.5 
EC 
1.4-1.8 0.19-0.65 EC 3.2-5.7 
(Kimura et al., 
2002) 
Green tea 640 (TC’s) 1.5 1.8 TC’s  - 
(van het Hof et al., 
1999) 
 
1040 
(TC’s/d for 
3days) 
0.5–2.0 1.0 TC’s - (Pietta et al., 1998) 
Table 1- Non-exhaustive list of bioavailability studies of catechins. (TC’s: total catechins) 
 
2.2 Metabolism of Catechins 
 
The major biotransformation reactions that GTCs undergo are methylation, 
glucuronidation, sulfation, and ring-fission metabolism (Li et al., 2001, 
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Kohri et al., 2001, Hu et al., 2003, Lu et al., 2003b, Lu et al., 2003a, Meng 
et al., 2002, Feng, 2006). 
2.2.1 Methylation  
 
Catechol-O-methyltransferase (COMT) is present in all tissues at high 
activity in humans and rodents, and catalyzes the metabolic O-methylation 
of various catecholic compounds (Axelrod and Tomchick, 1958). COMT 
has highest activity in liver, then kidney and gastrointestinal tract, and has 
been found in all mammalian tissues investigated which include human, 
mouse, and rat (Lu et al., 2003b). 
COMT enzyme studies (Lu et al., 2003b, Okushio et al., 1999b, Okushio et 
al., 1999a) show that the catechins are readily methylated to form: 3’-O-
methyl-catechin (Donovan et al., 1999), 4’-O-methyl-catechin (Donovan et 
al., 1999), 3’-O-methyl-EC (Okushio et al., 1999b, Okushio et al., 1999a), 
4’-O-methyl-EC (Okushio et al., 1999b, Okushio et al., 1999a), 4’-O-
methyl-EGC (Lu et al., 2003b), 4’’-O-methyl-ECG  (Okushio et al., 1999b, 
Okushio et al., 1999a), 4’’-O-methyl-EGCG (Okushio et al., 1999b, Meng 
et al., 2002), and 4’,4’’-O-dimethyl-EGCG (Lu et al., 2003b) (figure 3). 
 
Figure 3 - Structures of some methylated catechins indicating position of methylation 
(phenol explorer.eu) 
 
Epicatechin, and epigallocatechin were good substrates for metabolic O-
methylation by placental cytosolic COMT (150–500 pmol/mg of 
protein/min), but epicatechin gallate and epigallocatechin gallate were O-
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methylated at much lower rates (<50 pmol/mg of protein/min) (Zhu et al., 
2000). O-methylation by human placental COMT showed dependence on 
incubation time, cytosolic protein concentration, incubation pH, and 
concentration of S-adenosyl-L-methionine (the methyl donor).  
Rat liver cytosol shows higher COMT activity toward EGCG and EGC than 
human or mouse liver cytosol and the small intestine had lower specific 
activity than the liver in the methylation of EGCG and EGC. 
Glucuronidation on the B-ring or the D-ring of EGCG greatly inhibited the 
methylation on the same ring, but glucuronidation on the A-ring of EGCG 
or EGC did not affect their methylation (Lu et al., 2003b). 
Meng et.al chemically synthesized 4’-O-methyl EGC, 4’’-O-methyl EGCG, 
and 4', 4''-di-O-methyl- EGCG and confirmed their structures in human 
plasma and urine samples using LC/MS and found that 4’-O-methyl EGC 
and 4', 4''-di-O-methyl-EGCG were the major methylated metabolites of 
EGC and EGCG in humans (Meng et al., 2001, Meng et al., 2002). At low 
concentrations of EGCG, the dimethylated compound is the major product, 
whereas at high EGCG concentrations, monomethylated EGCG 
metabolites increase (Zhu et al., 2000, Okushio et al., 1999b, Lu et al., 
2003b).  
 
 
2.2.2 Glucuronidation  
UDP-glucuronosyltransferase (UGT)-catalyzed glucuronidation is a major 
pathway in Phase II metabolism. Catechins are conjugated to form the 
metabolites EGCG-7-Gluc, EGCG-4’’-Gluc, EGCG-3’’-Gluc, EGCG-3’-
Gluc, EGC-3’-Gluc, and EGC-7-Gluc, from EGCG and EGC (Li et al., 
2001, Lu et al., 2003a, Sang and Yang, 2008). Catechin 5-O-β- 
glucuronide and epicatechin 5-O-β- glucuronide were only found in rat, but 
have not been identified in human liver, human small intestine, and human 
colon microsomes (Harada et al., 1999, Vaidyanathan and Walle, 2002). 
Crespy et al identified 3 peaks on a HPLC profile for ECG glucuronidated 
metabolites using rat intestinal and liver microsomes, but glucuronidation 
positions of ECG were not reported in the paper. They also showed rat 
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intestinal microsomes exhibited higher activity on the galloyl group of ECG 
and EGCG compared to the flavonoid ring, whereas hepatic 
glucuronidation was higher on the flavonoid ring of EGCG and ECG 
compared to the galloyl groups (Crespy et al., 2004).  
Natsume et al purified and elucidated the chemical structure of 
glucuronidated epicatechin metabolites in human and rat urine after oral 
administration. Metabolites purified from human urine were  epicatechin-3'-
O-glucuronide, 4'-O-methyl-epicatechin-3'-O-glucuronide, and 4'-O-methyl-
epicatechin-5-O-glucuronide or 4'-O-methyl-epicatechin-7-O-glucuronide 
(according to 1H- and 13C-NMR, HMBC, and LC-MS analyses). The 
metabolites purified from rat urine were 3'-O-methyl-epicatechin, 
epicatechin-7-O-glucuronide, and 3'-O-methyl-epicatechin-7-O-
glucuronide. These compounds were also detected in the blood of humans 
and rats by LC-MS (Natsume et al., 2003). More recently, a new method 
identified EC-glucuronides in dogs (Mata-Bilbao Mde et al., 2007). EGCG-
4’’-Gluc was found to be the major metabolite formed by human, mouse, 
and rat microsomes (Lu et al., 2003a). Mouse small intestinal microsomes 
had the greatest catalytic efficiency for the formation of EGCG-4"-O-
glucuronide followed by mouse liver, human liver, rat liver, and rat small 
intestine.  
The UGT-catalyzed glucuronidation of EGC was much lower than that of 
EGCG. Again, mouse liver microsomes had the greatest catalytic 
efficiency for the formation of EGC-3’-O-glucuronide followed by human 
liver, rat liver, and rat and mouse small intestine (Lu et al., 2003a). Human 
UGT1A1, 1A8, and 1A9 had the highest glucuronidation activity toward 
EGCG (Lambert et al., 2007). In some instances Catechin and EC are 
completely conjugated in plasma, however, EGCG and ECG are notable 
exceptions amongst flavonoids and are present mainly as the 
unconjugated parent compound in plasma (Crespy et al., 2004).  
2.2.3 Sulfation 
 
The main sulfotransferase isoform in the human liver is SULT1A1 
(Vaidyanathan and Walle, 2002).  SULT1A1 and SULT1A3 have high 
expressions in the human small intestine (Sundaram et al., 1989, 
22 
 
Vaidyanathan and Walle, 2002). EGCG is time- and concentration 
dependently sulfated by human, mouse, and rat liver cytosol. The rat 
cytosol has the greatest activity to sulfate EGCG, followed by the mouse 
and the human liver cytosol. The sulfates of EC, EGC, and EGCG have 
been identified from rodent and human samples mainly through LC/MS 
analysis. However, the chemical structures of those sulphate metabolites 
have not been characterized. The active sites for sulfation of tea catechins 
are still unknown (Sang et al., 2011). 
In human urine samples, EGC-O-Sulfate and EC-O-Sulfate were the major 
sulfated metabolites formed from EGC and EC respectively (Li et al., 
2001). Recent results from mouse urine samples analysed using tandem 
mass spectrometry showed that methylated EGCG (or glucuronidated or 
sulfated EGCG) can be further glucuronided and/or sulfated (or 
methylated) to form the  mixed EGCG metabolites O-Methyl-EGC-O-
Sulfate, O-Methyl-epicatechin-O-Sulfate, M4-O- Sulfate, and M6-O- 
Sulfate (Lambert et al., 2007). 
2.2.4 Glucosidation and Thiol conjugation 
 
Sang and Yang identified a novel EGCG metabolite, 7-O-β-D-
glucopyranosyl-EGCG-4’’-O-β-D-glucupyranoside, in a mouse urine 
sample using liquid chromatography /electrospray ionization tandem  mass 
spectrometry. The structure of this metabolite was confirmed by analyzing 
the MSn (n = 1–4) spectra as well as comparing the MS/MS spectra of its 
product ions with those from EGCG and EGCG-4″-O-β-D-glucupyranoside 
standards. To their knowledge, this was the first report of the identification 
of a glucoside metabolite of EGCG in mammals. The results indicated that 
glucosidation represents a novel pathway in the metabolism of EGCG in 
mice (Sang and Yang, 2008).  
Catechin can be metabolised by tyrosinase to form a cytotoxic o-quinone, 
which reacts with glutathione to form mono-, bi-, and triglutathione 
conjugates of catechin and mono- and biglutathione conjugates of a 
catechin dimer (Moridani et al., 2001). When peroxidase and hydrogen 
peroxide were used, only monoglutathione conjugates of catechin were 
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formed. In the presence of NADPH, rat liver microsomes also catalyzed 
oxidation of catechin leading to glutathione conjugate formation.  
Sang et al found that EGCG can be oxidized by peroxidase and hydrogen 
peroxide and then reacted with cysteine or glutathione to form conjugates. 
The structures of the cysteine and glutathione conjugates of EGCG were 
identified using 2D NMR and MS. Two thiol conjugates of EGCG (2’-
cysteinyl EGCG and 2’’-cysteinyl EGCG) were identified by LC/ESI-MS2 
analysis from the urine samples of mice administered 200 or 400 mg/kg 
EGCG, i.p. These conjugates were not found in urine samples of mice 
after receiving EGCG at 50 mg/kg i.p. or in human urine following 
consumption of 3 g of decaffeinated green tea solids (containing 333 mg 
EGCG). They concluded that EGCG is believed to be oxidized to form 
EGCG quinone, which can react with glutathione or cysteine to form the 
thiol conjugates and that detectable amounts of thiol conjugates of EGCG 
are formed only after rather high doses of EGCG are given to the mice 
(Sang et al., 2005, Sang et al., 2011). It would be worthwhile to further 
study whether glucosidation of EGCG occurs in humans. Further studies 
are needed to determine whether glucosidation is similar to 
glucuronidation as a general biotransformation pathway to most of the 
dietary flavonoids. 
 
2.2.5 Microbial metabolites in colonic flora  
 
There is a distinctive flora present in the different portions of the 
gastrointestinal tract i.e. mouth, oesophagus, stomach, small intestine, and 
large intestine. The human colon contains microbes numbering in the 
trillions, coming from approximately 500 different species of bacteria, 
which have enormous hydrolytic and catalytic potential (Backhed et al., 
2005, Savage, 1977, Salminen et al., 1996).  
The colonic flora breaks down polyphenols to constituent compounds such 
as phenolic acids and their glycine conjugates. Bacterial enzymes catalyse 
many reactions including hydrolysis, hydrogenation, dehydroxylation, 
oxidation, ring cleavage, decarboxylation and rapid de-conjugation. 
Studies have demonstrated that uptake/absorption of GTCs in the small 
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intestine is relatively small.  The low absorption in the small intestine 
implies that the majority of ingested GTCs including those absorbed and 
metabolised will reach the colon where they come across the colonic 
microflora. It has been shown that colonic metabolism of tea catechins 
form the ring fission products 5-(3’,5’-dihydroxyphenyl)-ᵧ-valerolactone 
(M6’), 5-(3’,4’,5’-trihydroxyphenyl)- ᵧ -valerolactone (M4), and 5-(3’,4’-
dihydroxyphenyl)- ᵧ -valerolactone (M6) (Li et al., 2001, Li et al., 2000). 
Maximal urine concentrations of 8, 4, and 8 μM were shown for M4, M6, 
and M6’, respectively following ingestion of 200 mg EGCG. Anaerobic 
fermentation of EGC, EC, and ECG with human fecal microflora resulted in 
the production of M4, M6, and M6’ (Meselhy et al., 1997). Further 
degradation of these compounds by intestinal flora results in the formation 
of lower molecular weight phenolic acids. Urine samples collected at 6-48h 
contained detectable amounts of final catechin metabolites, including 4-
hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, 3-methoxy-4-hydroxy-
hippuric acid and 3-methoxy-4-hydroxybenzoic acid (vanillic acid) (Pietta 
et al., 1998). 
 
2.2.6 Active Efflux (Phase III metabolism) 
 
The multidrug resistance-associated proteins (MRP) are ATP-dependent 
efflux transporters that are expressed in many tissues and over expressed 
in many human cancers (Lambert et al., 2007, Leslie et al., 2001). MRP1 
is located on the basolateral side of cells and is present in nearly all 
tissues and transports compounds from the interior of the cells into the 
interstitial space (Leslie et al., 2001). MRP2 is located on the apical 
surface of the intestine, kidney, and liver, where it transports compounds 
from the bloodstream into the lumen, urine, and bile, respectively (Leslie et 
al., 2001). This process limits the bioavailability and cellular accumulation 
of many compounds, including green tea catechins. 
Recent studies on EGCG uptake in Madin-Darby canine kidney (MDCKII) 
cells showed that indomethacin (MRP inhibitor) increased the intracellular 
accumulation of EGCG, EGCG 4’’- O-methyl-EGCG, or 4’,4’’-di-O-methyl-
EGCG by 10-, 11-, or 3-fold overexpressing MRP1 (Hong et al., 2003). 
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Similarly, treatment of MRP2 overexpressing MDCKII cells with MK-571 
(an MRP2 inhibitor) resulted in 10-, 15-, or 12-fold increase in the 
intracellular levels of EGCG, 4’’-O-methyl-EGCG, and 4’, 4’’-di-O-methyl-
EGCG, respectively. Treatment of PGP overexpressing MDCKII cells with 
PGP (P-glycoprotein) inhibitors, however, resulted in no significant effect 
on the intracellular levels of EGCG or its metabolites.  Treatment of HT-29 
human colon cancer cells with indomethacin resulted in increased 
intracellular accumulation of EGCG and its methylated and glucuronidated 
metabolites (Hong et al., 2002). These data suggest a role for MRPs, but 
not PGP, in affecting the bioavailability of EGCG and its metabolites. Other 
studies showed that treatment of Caco-2 cells with MK-571 enhances 
apical to basolateral movement of EC and ECG (Vaidyanathan and Walle, 
2001, Vaidyanathan and Walle, 2003). MK-571 reduced the efflux of EC-
sulfates from the cytosol to the apical well, suggesting the EC-sulfates are 
also substrates for MRP2 (Vaidyanathan and Walle, 2001). Future studies 
should focus on the efflux transporters to determine if they efflux intact 
polyphenols preferentially compared to their metabolites, or vice versa.  
Lambert et al have suggested that the uptake of EGCG into HT-29 cells is 
mainly through passive diffusion (Lambert et al., 2007), others have 
demonstrated that ECG is a substrate for the monocarboxylate transporter 
(MCT). Inhibition of MCT-1 by benzoic acid or phloretin significantly 
reduced ECG uptake by Caco-2 cells (Lambert et al., 2007, Vaidyanathan 
and Walle, 2003).  
The combined effects of MRP1, MRP2, and MCT on the bioavailability of 
the tea polyphenols remain to be determined in vivo. The apical location of 
MRP2 suggests that it acts to limit EGCG bioavailability by actively 
exporting EGCG back into the intestinal lumen. The remaining fraction of 
EGCG would then be absorbed into the portal circulation, enter the liver, 
and could subsequently be effluxed by MRP2 located on the canalicular 
membrane of the hepatocytes. In contrast, MRP1 is located on the 
basolateral side of enterocytes, hepatocytes, and other tissues. Substrates 
of this pump are effluxed from the interior of the cells into the intestinal 
space. The role of MRP1 would be expected to increase the bioavailability 
of EGCG in vivo. The influence of MRP1 and 2 in vivo, however, is likely to 
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depend on their relative tissue distribution. It was reported that the MRP2 
mRNA level was over 10-fold higher than that of MRP1 in the human 
jejunum; therefore, efflux of EGCG by MRP2 may be predominant in the 
intestine, resulting in a decrease of EGCG bioavailability (Vaidyanathan 
and Walle, 2003, Vaidyanathan and Walle, 2001, Lambert et al., 2007, 
Taipalensuu et al., 2001).  
A more recent study investigated the kinetics of efflux transport of the four 
major catechins in Caco-2 cell lines, to provide comparison on the efflux 
transport between each catechin. The basal-to-apical transport of each 
GTC at concentrations ranging from 15 to 265 μM was examined using the 
Caco-2 cell monolayer model. Transported amount of GTC was measured 
by high performance liquid chromatography with electrochemical 
detection. Kinetic parameters, Vmax, Km and Vmax/Km were determined 
and compared among the four studied GTCs. The extent of basal-to apical 
transport was, in descending order, EC > EGC > ECG ≈EGCG (Chan et 
al., 2007). Future studies should focus on the bioavailablity of tea 
polyphenols and specifically their metabolites in vivo and the effects of 
MRPs 1 and 2 on in vivo bioavailability.  
 
 
2.3  Conclusions 
 
Green tea - along with its constituent catechins- is considered as an 
important component in nutrition to prevent lifestyle-related diseases 
especially cancer and other denegenerative diseases. The health benefits 
of green tea are often attributed to polyphenols especially EGCG, 
recognized as an effective chemo-preventive agent that holds the ability to 
scavenge free radicals and is certainly helpful against various cancers.. 
 
There are currently strategies such as phytosome complexes that have 
enough data to claim that essentially they can double the bioavailability of 
certain polyphenols such as EGCG (Kidd, 2009). This could improve 
efficacy without compromising on safety issues as the product is natural 
and not chemically modified or synthesised.   
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Future studies should focus on improving the bioavailability and biological 
activity of GTCs in vivo, improving the absorption and metabolism, hence 
improving the health benefits obtained from drinking green tea. A direct 
comparison should only be made between studies on bioavailability when 
methods, matrices, populations, and doses are kept constant, which would 
decrease the discrepancies between published data. If the studies are to 
reflect how people generally consume tea, then instead of one dose 
followed by immediate analysis of plasma or urine, another avenue to 
explore would be repeat dosing which would represent a normal person 
drinking a cup of tea every ~4hours. As the general view is that green tea 
has more beneficial effects on health, most of the studies are 
understandably on green tea. However, in the west black tea is much 
more widely consumed, so it would seem sensible to also pay more 
attention to bioavailability studies on black tea. 
 
 
It is also clear that in the case of catechins except EGCG, the catechins 
are usually found in plasma in the conjugated form, so more research 
needs to be done on the bioactivities of the metabolites circulating in the 
plasma. What would also be essential to include in further studies is the 
potential importance of colonic metabolites which are present in high 
concentrations in the urine 
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Chapter 3 – Absorption of green tea catechins in the oral 
cavity, and protection against Hydrogen peroxide-induced 
mitochondrial DNA damage 
 
Abstract 
 
Background: Green tea catechins have been shown to have poor 
absorption, extensive metabolism, and low bioavailability in humans. 
The oral cavity is constantly being challenged by ingested or 
environmental factors, which can have negative effects on the cells 
mitochondria. It was hypothesised that green tea catechins at 
concentrations achievable in the oral cavity could be absorbed into 
human oral cells and protect against H2O2 induced mitochondrial DNA 
damage. Methods: Human volunteer buccal mucosal cells and H400 
cells were used to measure absorption of catechins. Volunteers 
incubated green tea in the mouth for up to 15 minutes, whereas in H400 
cells, catechins were incubated for up to 60 minutes. For mtDNA 
damage analysis, physiological concentrations of catechins were added 
to H400 cells before being challenged by H2O2. Results: ROS levels in 
buccal mucosal cells were significantly reduced when green tea was 
incubated in the mouth for up to 15 minutes. In human buccal cells, only 
EGCG and ECG were absorbed, whereas in H400 cells, all four 
catechins EGCG, EGC, ECG, and EC were significantly absorbed over 
60 minutes. Physiological concentrations of catechins significantly 
protected H400 cells against H2O2 induced mtDNA damage; at 3 hours 
between 72.3 – 93.9 % (10 µM), and 35.4-88.5 % (2 µM). When 
incubating with catechins for 1 hour the protective effects were 46.2-78.7 
% (10 µM). The gallated catechins showed a greater absorption in H400 
cells than the non-gallated catechins. Conclusions:  catechin incubation 
with oral H400 cells resulted in significant absorption of catechins, and 
afforded significant protection against mtDNA damage. These data show 
a potential beneficial effect of green tea catechins in the oral cavity.  
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3.1 – Introduction 
 
The oral cavity consists of a specialised interface which includes 
the gingival epithelium (soft tissue) (Pollanen et al., 2003). Oral, sulcular, 
and junctional epithelium make up the gingival epithelium which is 
continuously challenged against ingested materials and microorganisms 
(Schroeder and Listgarten, 1997). The gingival epithelium protects the oral 
cavity and the connective tissue beneath it by acting as a physical barrier 
barring the invasion of any microorganisms; stimulating the entry of 
immune cells such as neutrophils via the secretion of chemokines and 
cytokines (Dale, 2002). It is also a source of antimicrobial products termed 
epithelial antimicrobial peptides (EAP), which have been shown to be 
effective against a varied range of microbes as well some viruses and 
yeast (Diamond et al., 2008, Schonwetter et al., 1995). Keratinised and 
non-keratinised layers make up the oral epithelium; the keratinised layer 
contains corneal, granular, spinous, and basal layers; and the non-
keratinised layer includes superficial, intermediate, spinous, and basal 
layers. These oral epithelial layers consist of stratified squamous 
epithelium. In direct contact with the oral epithelial cells is the lamina 
propria (dense connective tissue) which contains inter alia fibroblasts, 
salivary glands, blood vessels, and structural fibers (Sloan et al., 1991, 
Squier and Kremer, 2001, Abdulmajeed et al., 2013, Richard and Pillai, 
2010, Collins and Dawes, 1987).  
The oral cavity undergoes a large range of stress from ingested 
compounds, and possibly toxins or microbes; as well as chemical and 
mechanical damage which can inhibit its ability to safeguard organs and 
tissues underneath (Squier and Kremer, 2001). In spite of the oral mucosa 
encountering these stressors, the epithelial tissue in the oral cavity is 
regenerated constantly via cell division. Thus damaged DNA is repaired 
before mitosis as this is when DNA is most susceptible to damage from 
external stressors (Thomson et al., 1999, Bjarnason et al., 1999). If after 
this constant exposure to risk factors and external stressors genomic 
integrity is compromised, through discrete genetic changes at the 
molecular level, oral cancers can develop especially after exposure to the 
40 
 
main risk factors such as alcohol consumption and smoking (Cruz et al., 
2002). These factors account for approximately 60 % of oral cancers, 
whereas the remaining 40 % of cases are caused by unknown nutritional, 
environmental, genetic, or viral factors (Hashibe et al., 2009).   
Tea is the second most widely consumed beverage after water 
and has been studied widely for its health benefits against degenerative 
diseases, cancer, heart disease, and diabetes (Butt and Sultan, 2009, 
Higdon and Frei, 2003, Lambert et al., 2005, Weisburger, 1999, Yang et 
al., 1999a, Yang et al., 2006). The polyphenolic catechins of green tea 
(EGCG, ECG, EC & EGC) in particular have been studied for their 
beneficial effects on human health as they comprise the majority of the 
dry weight compounds of green tea (Graham, 1992, Lambert and Elias, 
2010, Sang et al., 2011).  
Tea studies have also shown benefits towards prevention of dental 
caries, halitosis, stress-induced inflammation, and oral malignancies 
(Tsao et al., 2009, Yamamoto et al., 2003, Srinivasan et al., 2008, 
Maruyama et al., 2011, Lodhia et al., 2008, Hirasawa et al., 2006, Zhang 
and Kashket, 1998, Ferrazzano et al., 2011, Magalhaes et al., 2009).  
Tea has been presented as a possible chemopreventive agent against 
oral squamous cell carcinoma (OSCC) in vitro by inhibiting angiogenesis 
(Masuda et al., 2002, Cao and Cao, 1999), apoptotic cell death (Hsu et 
al., 2002, Babich et al., 2005), and reducing cell growth (Cao and Cao, 
1999, Khafif et al., 1998, Elattar and Virji, 2000). 7,12-
dimethylbenz[a]anthracene (DMBA)-induced HBP carcinogenesis was 
also shown to be inhibited by tea, owing to possible inhibition of 
angiogenesis and induction of apoptosis (Li et al., 1999, Li et al., 2002).  
Green tea catechins can accumulate in saliva after consuming 2-3 cups 
of green tea; EGCG 5-22 μg/ml, EGC 12-44 μg/ml, EC 1.8-7.5 μg/ml, 
whereas EGC was not determined (Yang et al., 1999b), and after chewing 
2 g of green tea leaves for 5 minutes EC 6-28 μg/ml, EGC 14-160 μg/ml, 
EGCG 31-90 μg/ml, and ECG 11-28 μg/ml. Thus a total salivary catechins 
concentration of 12-260 μM can be achieved, which was shown to be able 
to inhibit oral cavity carcinoma cell proliferation (Lee et al., 2004). 
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Aims of study 
Oxidative stress from reactive oxygen species (ROS) was first proposed 
by Harman et al as a major factor in ageing via damage to nucleic acids 
and cellular components (Harman, 1956). Since  mitochondria are the 
target and production site of ROS (Harman, 1972), mitochondrial DNA is 
the target of oxidative ROS mediated damage, accumulating deletions and 
point mutations that can be transported and accrued in replicating cells 
(Miquel et al., 1983, Miquel et al., 1980, Fleming et al., 1982). 
Mitochondrial DNA (mtDNA) has a less proficient repair machinery in place 
compared to nuclear DNA, lacks protective histones, mutated molecules 
can be complemented by wild-type molecules (all of which help maintain 
the damage in cells), and has a mutation rate which is up to 15-fold higher, 
giving rise to the mitochondrial theory of ageing (Short et al., 2005). If 
these mutations are constant and begin to accumulate, they may reach 
sufficient levels to start causing damaging effects in the mitochondria, 
which can in turn lead to faster ROS production and mitochondrial 
dysfunction (Wallace, 2010). Dietary strategies for the prevention of 
excess ROS in the mitochondria may provide therapeutic effects in the 
oral cavity and other tissues where oxidative stress is prevalent. The aims 
of this study were therefore to investigate the absorption of green tea 
catechins and possible formation of metabolites in human buccal 
mucosal cells and immortalised H400 oral cell lines. It was hypothesised 
that exposure to catechins would protect oral cells against hydrogen 
peroxide induced mtDNA damage.  
3.2 – Materials and methods 
   3.2.1 – Chemicals and reagents 
 
Epigallocatechin-3-gallate, Epigallocatechin, Epicatchin-3-gallate, 
Epicatechin, Ascorbic acid, Hydrogen peroxide, Hydrocortisone 
Succinate, 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid 
(Trolox), cell lysis buffer, and 4,5-Dihydroxy-1,3-benzenedisulfonic acid 
disodium salt monohydrate (Tiron) were purchased from Sigma Aldrich 
(Gillingham, UK). Green tea (Clipper fair trade pure green tea) for the 
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human study was purchased from the local supermarket.  2’, 7’-
Dichlorodihydrofluorescin-Diacetate (DCFH-DA) for the intracellular 
antioxidant assay was obtained from Cambridge Bioscience Ltd, 
Cambridge. The following were acquired from Life Technologies 
(Invitrogen): Dulbecco’s modified Eagle’s medium [DMEM:HAMS F12 
(1:1)]; RPMI-1640 medium; foetal Bovine serum (FBS); Trypsin-EDTA; 
and L-Glutamine. HPLC-grade Acetonitrile; phosphoric acid; and 
methanol were purchased from Fisher scientific (Leicestershire, UK). 
UPLC-grade Acentonitrile; UPLC-grade methanol; and Formic acid 
were purchased from Biosolve BV (Valkenswaard, Netherlands). 
SYBR-green was obtained from Applied Biosystems (Life 
Technologies, Netherlands). Primers for Mitochondrial DNA fragments 
were purchased from Eurofins Genomics (Ebersberg, Germany). The 
Genomic DNA purification kit was purchased from ThermoScientific 
(Leicestershire, UK). The cell fractionation kit, consisting of the 
membrane and cytoplasmic isolation buffers; was obtained from cell 
signalling technology (New England Biolabs, Hertfordshire UK).  
3.2.2 – Human intervention study 
 
Nine volunteers were recruited for this small pilot study to determine 
the antioxidant capacity and absorption of green tea catechins in the 
oral mucosa. All participants were given detailed information about the 
experimental procedures and what was expected of them if they agreed 
to take part in the study. A Q&A visit was also scheduled so that the 
volunteers could ask questions and clear up any uncertainties they 
had. Volunteers were then signed an informed consent form before the 
commencement of the study. Volunteers were asked to avoid flavonoid-
rich beverages and foods for 3 days prior to the study. Compliance was 
assessed via participant food diaries. Volunteers brushed the inside of 
their cheeks with their toothbrush the night before the experiment and 
did not have breakfast on the morning of the study days, each 
participant was sampled at every time point with each study day being 
assigned a different time point. Before drinking the green tea, 
participants brushed the inside of their left cheek and rinsed the cheek 
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with a 0.9% NaCl solution (baseline untreated cells). In this case these 
cells were used as control cells rather than using hot water as a 
control, as the participants did not consume any breakfast on the 
morning of the study days. This would have had minimal impact on the 
subsequent data obtained. Thereafter, freshly prepared green tea (one 
tea bag brewed in 450 mL boiling water) was held within the mouth 
over a period of 2.5 - 20 minutes and the buccal cells were collected 
from the right cheek (treated cells).  Both sets of samples were washed 
three times with cold RPMI buffer, and then split into three equal 
aliquots, for the antioxidant assay and HPLC analysis of intracellular 
extracts.  
   3.2.3 – Antioxidant assay 
 
Baseline, Trolox, and green tea treated cells were incubated with 100 
µL of DCFH-DA solution for 1 hour and then incubated for 1 hour with 
200 µM H2O2. The cells were lysed with cell lysis buffer, centrifuged, 
and the supernatant analysed with a fluorometric plate reader at 480 
nm Excitation/530 nm Emission wavelengths. The principle of the 
DCFH-DA assay was to measure intracellular ROS activity. DCFH-DA 
is deacetylated via the action of cellular esterases after diffusing into 
cells into a non-fluorescent DCFH, which in turn is oxidised to DCF 
which is highly fluorescent. This in turn gives a proportional fluorescent 
intensity based on the intracellular ROS levels (cellbiolabs, oxiselect 
intracellular ROS assay kit).  
3.2.4 – HPLC analysis 
 
HPLC-PDA (photo-diode array) detection was used to analyse the 
intracellular extracts of human volunteer buccal cells using a 
Phenomenex C18 column (250mm x 4.6mm i.d., 5µm) and was 
operated at 40 oC. Buccal cells were extracted thrice with 200 µL of 
methanol, dried under nitrogen gas, and re-suspended in 50:50 mobile 
phase A and B. Peak areas were measured at 270nm and UV spectra 
were recorded from 190nm to 370nm on the HPLC system (Shimadzu, 
Japan). The system consisted of a SIL-20AC auto-sampler, an LC-
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20AD liquid chromatogram, SBM-20A communication bus module, 
DGU-20AD degasser, CTO-20AC column oven, and an SPD-M20A 
photo-diode array detector. The equipment was operated using the 
Shimadzu LC solution software. The mobile phases used were (A) 
0.1% phosphoric acid in water (w/v) and (B) acetonitrile. The sample 
injection volume was 20µL. The mobile phase gradient profile was as 
follows: 8% B for 2.5 minutes, increasing to 18% at 14.25 minutes, 24% 
at 19.5 minutes, 26% at 20 minutes, 28% at 23 minutes, and back 8% 
at 27 minutes. The flow rate was set at 1mL/min. The catechins in the 
buccal cells were identified by comparing their retention times and UV 
spectra with authentic standards. Concentrations were obtained using 
standard curves of the individual catechins. 
3.2.5 – Cell culture 
 
H400 cells (human oral squamous cell carcinoma, from the alveolar 
process) were routinely cultured in Dulbecco’s modified Eagle’s 
medium DMEM:HAMS F12 (1:1), supplemented with 10% Foetal 
bovine serum (FBS), 2 mM Glutamine, and 0.5 µg/mL sodium 
hydrocortisone succinate. All cells were cultured and maintained in 75 
cm2 flasks, with the environment controlled at 37 oC and 5 % CO2. The 
cell medium was changed every 2 days (3 times per week), and cells 
were sub-cultured at 80 % confluence. For absorption and adsorption 
of catechins, 6-well plates were used and catechins were added at 100 
µM with 10 µM ascorbic acid to keep the catechins stable. Catechins 
were stable in the presence of cells and ascorbic acid for 90 minutes. 
For the measurement of mitochondrial DNA (mtDNA) damage; 12-well 
plates were used and were incubated with catechins at 10 µM & 2 µM. 
Ascorbic acid was co-incubated at 5µM. Experiments were carried out 
4 days post-seeding when cells were 100 % confluent. H400 cells at 
passage 27-39 were used for all experiments.  
To analyse the cytoplasmic and membrane fractions: the cells were 
first trypsinised and washed with cold PBS; centrifuged at 500 x g for 5 
minutes at 4 oC, and the pellet resuspended in 500 µL of cytoplasmic 
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isolation buffer (CIB). The pellet was vortexed, centrifuged at 500 x g 
for 5 minutes, and supernatant removed (cytoplasmic fraction). The 
remaining pellet was re-suspended in membrane isolation buffer (MIB), 
vortexed and centrifuged at 8000 x g for 5 minutes. The supernatant 
was removed for analysis (membrane fraction).  
3.2.6 – Acquity ultra performance liquid chromatography (ULC)-MS 
analysis of H400 cell extracts 
 
Analysis of catechins in H400 cell cytoplasmic and membrane fractions 
were carried out using an XBridge C18 column (5mm x 4.6mm i.d., 
3.5µm) on an Acquity ULC system (Waters, UK). A Synapt-G2 HDMS 
(Waters) provided the mass spectrometric detection in negative 
ionisation electrospray mode. The sampling cone voltage was set at 35 
V; desolvation temperature at 350oC; and source temperature at 
100oC. Leucine Enkephalin (2 ng/mL) was used as a reference 
compound in negative ion mode (m/z 554.2648). A flow rate 0.3 mL/min 
was used and column temperature was maintained at 35oC.  The 
mobile phases were (A) 0.1 % Formic acid in water (w/v) and (B) 0.1 % 
Formic acid in acetonitrile. The sample injection volume was 3 µL. 
Initial conditions were 3 % B for 1 minute, increasing to 18 % B at 6 
minutes, staying constant at 18 % B until 6.5 minutes, back to 3 % B at 
6.6 minutes, and then stayed at 3 % B until 8 minutes. Accurate 
masses were obtained using Masslynx 4.1 software, with scanning 
across the spectrum of 50-1000 m/z, and concentrations were obtained 
using standard curves of the individual catechins. 
3.2.7 – Analysis of mtDNA damage  
 
H400 cells were cultured in 12-well plates to 100 % confluence. They 
were then washed twice with warm PBS, and incubated with 10 µM and 
2 µM catechins for 1 hour and 3 hours in culture medium. Cell culture 
medium was removed, cells washed twice with PBS, and mitochondrial 
DNA (mtDNA) damage was induced by exposing the cells to 1 mM 
H2O2 for 24 hours. The H2O2 was removed and genomic DNA was 
extracted using a cultured mammalian cells Genomic DNA purification 
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kit (ThermoScientific). The total assay volumes for PCRs was 25µL, 
which included 40ng of extracted DNA, forward and reverse primers, 
and a SYBR green PCR master mix. The 7500 RT-PCR sequence 
detection software (version 1.3.1, Applied Biosystems) and Applied 
Biosystems 7500 RT-PCR machine was used for the assays. 
Mitochondrial DNA damage was expressed as a Ct value (cycles to 
threshold) fold difference of a long (972bp) mtDNA fragment in relation 
to a short (83bp) fragment mtDNA. The short fragment was undamaged 
at 1mM H2O2 and acted as an internal standard. The Ct value is 
inversely proportional to the quantity of DNA and is measured 
logarithmically as the amount of DNA is theoretically doubled in every 
PCR cycle.  
 
The primers used were as follows:  
Long fragment (972bp) – AL4_F (forward): 5’-
CTGTTCTTTCATGGGGAAGC-3’ AS1_R (reverse): 5’-
AAAGTGCATACCGCCAAAAG-3’ 
Short fragment (83bp) – IS1 (forward): 5’-
GATTTGGGTACCACCCAAGTATTG-3’  
IS2 (reverse): 5’-AATATTCATGGTGGCTGGCAGTA-3’. The PCR 
program for the long fragment amplification was as follows: 1 cycle at 
95°C for 10 minutes, 40 cycles at 95°C for 15 seconds, 60°C for 15 
seconds, 72°C for 55 seconds. For the short fragment amplification the 
PCR program was: 1 cycle at 95°C for 10 minutes, 40 cycles at 95°C 
for 15 seconds, 60°C for 15 seconds, 72°C for 15 seconds.  
 
3.2.8 – Statistical analysis  
 
All data were analysed using GraphPad Prism 5.03 (GraphPad 
software Inc. La Jolla, California). Values were expressed mean ± SD 
and represented as a difference in Ct values in comparison to untreated 
controls. A one-way ANOVA with Newman-Keuls multiple comparison 
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tests were carried out to measure statistical significance. Differences 
were considered significant if p values were <0.05.  
For the antioxidant capacity in human volunteer oral cells, students t test 
was used to measure statistical significance (n=9).  
 
3.3 – Results 
3.3.1 – Antioxidant capacity and absorption of catechins in human 
volunteer oral cells 
 
The antioxidant DCFH-DA assay showed that ROS levels were 
significantly reduced in the green tea treated compared to baseline 
control cells. A significant decrease in ROS levels was observed after 
green tea was left in the mouth or consumed over 2.5 minutes 
(p=<0.05). There were also significant reductions in ROS levels at 5 
minutes (p=<0.01), 10 minutes (p=<0.01), and 15 minutes (p=<0.01) 
(Figure 3.1). The largest reduction in ROS levels was observed 
between 2.5 and 5 minutes. From 5 to 10 minutes of incubation there 
was further slight decrease in ROS levels, but there was no further 
significant reduction after 10 minutes of incubation.  
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Figure 3.1 –Reduction in ROS levels in oral buccal cells after green tea incubation in 
the oral cavity. The results are compared to the baseline cells at 0 minutes with no 
exposure to green tea. Results are expressed as mean ± SEM, n=9.   
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Catechin concentrations were obtained through HPLC analysis of 
buccal cell extracts in combination with HPLC standard curves. After 
2.5 minutes of green tea incubation only ECG was detected among all 
samples. EGCG was only detected in 1 sample after 5 minutes of 
exposure. However, after incubating green tea for 10 minutes there 
was a large increase in uptake of both ECG and EGCG (Figure 3.2), 
however this may have also meant that the 2 compounds became 
detectable under these conditions at this time point. At 15 minutes, 
ECG showed no further increase in absorption, whereas EGCG was 
increasingly absorbed in a time-dependant manner. In all samples and 
all time-points, EGC and EC were not detected.  
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3.3.2 – LC/MS analysis of H400 cells 
 
Catechins were analysed via HPLC-MS after incubation with 
H400 cells for 10-60 minutes. In agreement with the results from the 
human volunteer samples, there was significant uptake of the gallated 
catechins EGCG and ECG. Both these catechins were rapidly absorbed 
Figure 3.2 – Absorption of catechins in human volunteer buccal cells after 
incubation of green tea in the oral cavity for 2.5-15 minutes. Values are 
standardised with mean ± SD, n = 9. 
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until the 20 minutes time-point, and then plateaued off from 30 until 60 
minutes (figure 3.2).  ECG was absorbed into the buccal cells at peak 
levels of 11.22 µM at 60 minutes and EGCG also reached a peak 
concentration at 60 minutes (9.08 µM). The concentration absorbed into 
oral cells in cell culture was very similar for the first ten minutes, after 
which EGCG absorption slowed down and plateaued seemingly earlier 
than ECG (Figure 3.3).  
 
ECG
0 20 40 60
0
5
10
15
20
Time (minutes)
A
b
s
o
rp
ti
o
n
 (
µ
M
)
EGCG
0 20 40 60
0
5
10
15
Time (minutes)
A
b
s
o
rp
ti
o
n
 (
µ
M
)
 
Figure 3.3 – Absorption of EGCG and ECG in oral H400 cells. Concentrations are 
expressed as µM/well in 6-well plates with the cell layers at 100% confluency. 
Values are means ± SD, n=6 (over 2 experiments in triplicate) . 
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The results also showed the comparatively lower uptake of the non-
gallated catechins in the oral cells as compared to EGCG and ECG. 
However, due to the increased incubation times when using the H400 
cells and increase in detection limits of the UPLC-MS compared to diode 
array HPLC, EGC and EC were also detected, albeit in smaller but still 
significant quantities (figure 3.5).  Cell membranes were also analysed 
via UPLC/MS to locate the proportion of catechins that were located on 
the cell surface and membrane compared to the cell plasma and cell 
organelle.  No catechins were detected in the membrane fraction using 
UPLC/MS. Furthermore, no metabolites of catechins were found in the 
oral cells (both volunteer buccal cells and H400 cells) via analysis of a 
full m/z scan or 50-1000 m/z (figure 3.4).  
 
Figure 3.4 – LC chromatograms of EGCG (A), ECG (B), and epicatechin (C). The m/z peaks on the bottom 
half show parent catechins, with 2 peaks of epigallocatechin and epicatechin-gallate dimers (m/z 611.1342 
and 883.1708 respectively). The m/z scan from 100 – 1000 m/z shows no metabolites for any of the parent 
catechins in any of the oral cell extracts, confirming the lack of phase 2 metabolism of catechins in the oral 
cavity. 
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3.3.3 – Protective effects of catechins against mitochondrial DNA 
damage in oral H400 cells 
 
 An optimal concentration of 1 mM H2O2 for 24 hours was chosen 
for these experiments after extensive dose response experiments were 
Figure 3.5 – Absorption of EGC and EC in oral H400 cells. Values are means ± 
SD, n=3. Concentrations are expressed as µM/well in 6-well plates with the cell 
layers at 100% confluency. Values are means ± SD, n=6 (over 2 experiments in 
triplicate). 
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carried out to find the optimum sub-lethal dose of H2O2. After 
incubation of catechins with H400 cells for 3 hours, there was a 
significant reduction in mtDNA damage with all 4 catechins at 10 µM 
(figure 3.6 and table 3.1). At 2 µM catechin concentrations, all but EGC 
showed significant protection against mtDNA damage, although 
statistically this was also significant at 2 µM.  With the protective effects 
seen at 3 hours of catechins incubation, the time of catechin exposure 
was reduced to 1 hour (figure 3.7). At this time-point the gallated 
catechins EGCG and ECG showed the highest protection against 
mtDNA damage, even at 2 µM. 10 µM EGC and EC still displayed 
significant protection after 1 hour (table 3.2); however this was reduced 
markedly when the concentration was reduced to 2 µM.   
      
 
 
Treatment comparison (3 hours) % protection P  
Tiron vs H2O2 95.8 0.001 
10µM EGCG vs H2O2 93.9 0.001 
2µM EGCG vs H2O2 88.5 0.001 
10µM EGC vs H2O2 72.3 0.001 
2µM EGC vs H2O2 35.4 0.05 
2µM EC vs H2O2 80.4 0.001 
10µM EC vs H2O2 83.5 0.001 
10µM ECG vs H2O2 79.6 0.001 
2µM ECG vs H2O2 69.6 0.001 
TABLE 3.1 - H400 cultured cells pre-treated for 3 hours with catechins 
and Tiron (2mM). *P < 0.05, ***P < 0.001 vs. H2O2 treatment; 1-way ANOVA 
with Newman-Keuls multiple comparison test. (n=6 over 2 experiments in 
triplicate) 
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Figure 3.6 – Protective effects of 3 hours EGCG, EGC, ECG, and EC incubation 
against mtDNA damage in H400 cells. The damage is induced by subsequent 
exposure to 1mM H2O2 for 24 hours. The control is free from any antioxidant or 
oxidative damage inducer. A one-way ANOVA with Newman-Keuls multiple 
comparison tests were carried out to measure statistical significance of tiron and 
catechin treated cells in comparison to other catechins (shown on graph) and H2O2 
treated cells. The data was normalized and values expressed as mean ± SD.  
*P<0.05, *** P<0.001. (n=6 over 2 experiments in triplicate) 
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Figure 3.7 – Protective effects of 1 hour EGCG, EGC, ECG, and EC incubation 
against mtDNA damage in H400 cells. The damage is induced by subsequent 
exposure to 1mM H2O2 for 24 hours. The control is free from any antioxidant or 
oxidative damage inducer. A one-way ANOVA with Newman-Keuls multiple 
comparison tests were carried out to measure statistical significance of tiron and 
catechin treated cells in comparison to other catechins and H2O2 treated cells. The 
data was normalized and values are expressed as mean ± SD.  * P<0.05, *** 
P<0.001. (n=6 over 2 experiments in triplicate) 
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Treatment comparison (1 hour) 
 
% Protection P  
 
2µM EGCG vs H2O2 83.2 0.01 
10µM EGCG vs H2O2 78.7 0.01 
10µM EGC vs H2O2 53.8 0.05 
Tiron vs H2O2 50.3 0.05 
10µM ECG vs H2O2 76.8 0.01 
2µM ECG vs H2O2 67.1 0.01 
10µM EC vs H2O2 46.2 0.05 
 
 
 
The results also confirmed that Tiron offered 100 % protection against 
H2O2-induced mtDNA damage at more than 2 hours of incubation 
which was shown in a previous study (Oyewole et al., 2014), and was 
therefore used as a positive control in all experiments. From the levels 
of catechins absorbed in H400 cells, there was a correlation between 
the levels of absorption and the degree of protection afforded against 
mtDNA damage. At 1 hour of incubation, EGCG and ECG were the 
highest absorbed catechins and also conferred the highest amount of 
protection against mtDNA damage. At 3 hours of incubation with 
catechins, EGCG showed the highest protection followed by EC and 
ECG. EGC was the least effective at protecting mtDNA from damage 
when compared with the other three catechins, but still had significant 
protection (*p<0.05).  
 
 
 
 
 
TABLE 3.2 - H400 cultured cells pre-treated for 1 hour with catechins and Tiron 
(2mM). *P < 0.05, **P < 0.01, vs. H2O2 treatment; 1-way ANOVA with Newman-
Keuls multiple comparison test. 
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4 – Discussion 
 
The main objectives of this study were to determine the intracellular 
levels of catechins in oral cells and whether or not they could protect 
against mtDNA damage in these cells. The studies showed significant 
absorption of catechins into human oral H400 cells of all four catechins, 
and also significant protection of mtDNA in oral cells.  
There are various studies which support the theory that green tea plays 
a significant role in maintaining good oral health. For example it was 
shown that dentine was protected from erosion and abrasion by rinsing 
the mouth with a 0.61% green tea extract (Magalhaes et al., 2009). 
Green tea in mouthwash was also able reduce the salivary levels of 
Lactobacillus and streptococcus mutans which cause caries 
(Ferrazzano et al., 2011). Mucins, histatins, oral peroxidases, 
lactoferrin, lysozyme, and secretory immunoglobulins are protective 
salivary components which are released indirectly from the salivary 
glands via green tea, which could lead to its indirect effects as an 
antimicrobial in the oral cavity and therefore prevent the formation of 
dental caries (Zhang and Kashket, 1998). Green tea was also shown to 
be effective against bacterial halitosis by the inhibition of formation of 
volatile sulphur compounds, and followed by inserting green tea 
catechins into treatments like mouth spray and chewing gum for bad 
breath (Lodhia et al., 2008, Zeng et al., 2010). It was found that 
salivary levels of catechins were quite high (2-260 µM) compared with 
plasma concentrations when a tea solution was held in the mouth or via 
chewing tea leaves (Yang et al., 1999b, Lee et al., 2004). Of course it 
was recognised that to elicit any health effects this would not be 
achieved via a single dose to the oral cavity; instead chewing green tea 
leaves to release catechins to the oral cells would be far more effective. 
Yang et al and Lee et al demonstrated that pharmacological 
concentrations could be achieved in the mouth by chewing/holding 
green tea leaves or tea in the mouth, effectively providing safe, cheap, 
and widely accepted health benefits. For aesthetic purposes lozenges 
or chewing gum with sustained release properties could be developed 
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to deliver catechins to the oral cavity and even to the stomach or 
intestine for example. 
This is the first study to determine intracellular levels of catechins 
within the oral mucosa and to measure the protective effects of those 
catechins against mitochondrial DNA damage in the oral cavity. When 
samples were taken from human volunteers, there were only small 
amounts of samples so the amount of catechins adsorbed onto the cell 
membranes could not be measured; in those samples only EGCG and 
ECG could be detected in the buccal mucosa. The aim was to measure 
catechins stickiness on oral cell membranes using oral H400 cells, as 
polyphenols have been shown previously to be able to bind to the 
surface of red blood cells and microbes (Ginsburg et al., 2011, Koren et 
al., 2010, Koren et al., 2009). The oral cavity includes the resident 
microbiota, teeth, gingiva, oral mucosa, and tongue which can be 
possible sites for polyphenols to stick to (Schroeder and Listgarten, 
1997, Dale, 2002). Aside from the possibility of adhering to the external 
cell membranes, a recent study demonstrated that an anthocyanin 
glucuronide and its microbial metabolite were detected in the oral 
cavity, which shows uptake and phase II metabolism as well as 
microbial degradation in the oral cavity (Mallery et al., 2011). There 
have been no previous reports of microbial or phase I/II metabolites of 
catechins found in the oral cavity, however Yang et al did find activity of 
a catechin esterase which cleaved EGCG into EGC in the saliva (Yang 
et al., 1999b). In our study there were no catechins found stuck to the 
H400 cell membranes which agreed with the theory that  polyphenols 
only become ‘sticky’ in the presence of a synergistic effect of microbes, 
salivary low molecular weight antioxidants, blood cells, salivary proteins 
such as albumin, and other polyphenols, i.e. in vivo (Koren et al., 2010, 
Ginsburg et al., 2012, Ginsburg et al., 2013). However, significant 
quantities of catechins were detected in the intracellular fractions of 
H400 cells, suggesting that saliva and microorganisms play a minimal 
role in absorption of green tea catechins in the oral cavity. Due to the 
lack of salivary catechin esterase in cell culture, a lack of EGC in the 
EGCG incubation was observed. UGT1A10 is an extrahepatic phase II 
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enzyme found in the oral cavity but is not one of the UGTs involved in 
metabolising green tea catechins (Strassburg et al., 1999, Tukey and 
Strassburg, 2000, Tukey and Strassburg, 2001, Feng, 2006). Based on 
previous studies using salivary catechins and from the levels of 
catechins that were measured in H400 cells, it is clear that the oral 
cavity is exposed to unchanged parent catechins which act as very 
powerful antioxidants (Lambert and Elias, 2010, Henning et al., 2004, 
Khan et al., 2008). The results from our antioxidant capacity study 
demonstrate that having tea in the mouth for even 2.5 minutes reduces 
the ROS levels in the oral buccal mucosa significantly. These catechins 
can, if individuals drink green tea regularly (3-4 cups daily, or chew tea 
leaves) act as first line of defence against ingested pathogens, which 
not only has beneficial implications for good oral health but 
downstream health benefits for a healthy gastrointestinal tract.  
Mitochondrial DNA (mtDNA) is highly susceptible to oxidative damage 
because mitochondria are the major site of superoxide production in 
the cell, which is then altered into other ROS (Birch-Machin and 
Swalwell, 2010, Murphy, 2009). If the site of mtDNA is constantly 
exposed to oxidative damage constantly, this can lead to mutations in 
the DNA; which has been suggested as one of the principal causes of 
tissue ageing and carcinogenesis (Tulah and Birch-Machin, 2013). It 
was proposed that exposing oral cells to physiological concentrations 
of catechins would protect against hydrogen peroxide induced mtDNA 
damage, mainly because polyphenols act as powerful antioxidants 
which efficiently scavenge intracellular superoxide and other ROS 
species which can protect cells and tissues against oxidative damage 
(Hseu et al., 2012, Liu et al., 2011, Tobi et al., 2002, Stewart et al., 
1996, Offord et al., 2002, Morley et al., 2003, Morley et al., 2005, 
Marrot et al., 2008, Eicker et al., 2003, Chan et al., 2003). Tiron was 
used as  a positive control in our study as it was previously shown to be 
100% effective at protecting mtDNA against oxidative damage, and that it 
is a mitochondria-permeable antioxidant (Oyewole et al., 2014, Supinski 
et al., 1999, Silveira et al., 2003, McArdle et al., 2005, Krishna et al., 
1992). The oral cavity is the first point of contact for ingested materials 
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and therefore the first to be exposed to any beneficial or harmful 
compounds hence is a very important target to keep as healthy as 
possible. Giving green tea as a beverage or an extract can make it 
unclear whether the potency is because of the individual of catechins or 
a synergistic combination of its other constituents. In this study, H400 
cells were exposed to 10 µM and 2 µM of individual catechins for 1 and 
3 hours, thereafter stressed via 1 mM H2O2 for 24 hours to induce 
significant amounts of mtDNA damage. After 3 hours of incubation 
EGCG was found to be the most effective at both 10 and 2 µM at 
protecting against mtDNA damage, followed by EC, ECG, and EGC, 
which also had very significant amounts of protection. This correlated 
well with antioxidant capacity as EGCG was shown to be the most 
effective antioxidant of the major catechins in tea (Stewart et al., 2005). 
The time was then reduced further to 1 hour to make conditions as 
physiological as possible, but the concentrations were kept the same. 
Even at 1 hour of catechin exposure there was very significant 
protection with both 10 and 2µM of EGCG and ECG, and significant 
protection observed with only 10µM of EGC and EC. After 1 hour of 
exposure to 100µM individual catechins, intracellular levels of EGCG 
and ECG reached 9.1 and 11.2µM respectively. At the same time-point 
levels of EGC and EC were 5.1 and 3.2µM respectively, which could 
explain the higher levels of protection conferred by EGCG and ECG. 
Further studies should include measuring mtDNA damage in human 
buccal cells whilst drinking green tea as it is normally consumed 
instead of swishing it in the mouth or holding/chewing tea leaves. This 
would give the best indication of the exact physiological effects that the 
catechins have in the oral cavity with regards to absorption and 
protection against oxidative mtDNA damage. This has significant 
implications for general oral health and prevention of oral diseases, and 
provides a sound strategy for safe nutritional interventions for 
combating ROS mediated damage in the oral cavity.  
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Chapter 4 - Metabolism of green tea catechins by COMT, 
human liver, and intestinal phase II enzymes 
 
Abstract 
 
Background: Green tea catechins are extensively conjugated after 
ingestion via intestinal and hepatic phase II enzymes. These UGTs, 
SULTs, and COMT produce glucuronide, sulfate, and methylated 
metabolites. It is vital to understand the exact metabolites formed in 
different tissues so this can potentially be correlated with their 
production and bioactivity in vivo. This study aimed to determine the 
metabolism of green tea catechins over 3 hours after incubation with 
different phase II enzyme fractions with the purpose of producing 
sufficient amounts of metabolites to use in further experiments (mtDNA 
damage in chapter 5). Methods: catechins (200 µM) were incubated 
with phase II enzymes for up to 3 hours. Samples were removed at 
regular time-points to measure the exact amount of metabolites formed 
over that period. Results: Catechins were not extensively sulfated using 
s9 or liver cytosolic fractions. The major sulfates produced were 3’-O-
methyl-EC-sulfates and 4’-O-methyl-EGC-sulfates. EGCG and EGC 
were significantly methylated via porcine COMT, and EC was 
metabolised to a lesser extent. Glucuronidation was the major conjugate 
forming pathway in our experiments. Methylation of EGCG at the 4’ 
position (4’O-methyl-EGCG) and methylation of 4’-O-methyl-EGC at the 4’ 
position greatly increased glucuronidation via liver microsomes. 4’-O-
methyl-EGC was also sulfated much more efficiently than EGC. When EC 
was methylated at the 3’ position, its capacity for sulfate conjugation 
greatly increased. Conclusions:  The results from our metabolism 
experiments showed extensive glucuronidation of catechins, and also 
significant amounts of methylation. These can be used as preliminary 
studies to plan more extensive metabolism experiments in future.  
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4.1– Introduction 
 
In recent years the polyphenolic catechin compounds in green tea have 
been widely studied for their health benefits. The observed health effects 
of these flavonols include the prevention of cardiovascular diseases, 
diabetes, neurodegenerative diseases, and cancer (Yang et al., 2006, 
Lambert and Elias, 2010, Higdon and Frei, 2003). The catechins account 
for 30-40% of the dry weight of which the main ones are; 
Epigallocatechin-3-gallate (EGCG), Epicatechin-3-gallate (ECG), 
Epigallocatechin (EGC), and Epicatechin (EC) (Balentine et al., 1997).  
Many studies have used intact forms of catechins in vitro to assess their 
potential effects on health; however this is not the case in vivo where 
extensive metabolism occurs via glucuronidation, sulfation, and 
methylation (Yang et al., 1998, Van Amelsvoort et al., 2001, Stalmach et 
al., 2009, Lee et al., 2002). These studies showed that catechins as well 
as their metabolites occurred in urine and plasma, and reached 
micromolar concentrations. This has been confirmed in vitro where the 
UGT-mediated glucuronidation (Vaidyanathan and Walle, 2002, Lu et 
al., 2003a, Crespy et al., 2004), sulfation via Sulfotransferases 
(Vaidyanathan and Walle, 2002, Feng, 2006), and methylation via 
COMT (Zhu et al., 2000, Lu et al., 2003b) of catechins were studied.  
As there are so many different metabolites formed from catechins, it is of 
utmost importance therefore to understand the precise metabolism of 
these catechins to determine their bioactivities. EGC and EC, the non-
gallated catechins are usually found in the plasma in their conjugated 
forms (69 % and 79 % respectively), with major products being 4’-O-
methyl-EGC-sulfate, 4’-O-methyl-EGC-glucuronide, 4’-O-methyl-EGC, 
and 3’ / 4’-O-methyl EC (Feng, 2006). Gallated catechins such EGCG on 
the other hand, are generally in the plasma in their non-conjugated 
forms (77 – 90 %), where catechol-O-methyl transferase mediated 
methylation occurs for a small amount of EGCG (Lu et al., 2003b). Due 
to extensive metabolism and poor absorption, only 0.1 – 1 % of ingested 
green tea catechins reach the systemic circulation in humans (Chow et 
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al., 2001, Zhang et al., 2004).  
When compounds are metabolised, they are generally considered to be 
biologically inactive, or less bioactive than the parent compounds (Yano 
et al., 2007, Landis-Piwowar et al., 2008, Duenas et al., 2010), and are 
effectively marked for excretion via urine or bile. However, a few studies 
have shown that these metabolites of drugs and dietary compounds can 
also remain biologically active, and in some cases exert a higher 
bioactivity (Monks et al., 2004, Harris et al., 2004, Bai et al., 1999, Sano 
et al., 1999, Koga and Meydani, 2001, Chiu and Lin, 2005).  
For this reason, the determination of precise metabolism of green tea 
catechins is of vital significance, as more comprehensive data will make 
it easier to correlate the different metabolites to their potential in vivo 
health effects. As the detailed ADME properties of catechins are 
extremely important to increase our understanding of their mechanisms 
of action in vivo, and their overall contribution to the prevention of 
chronic diseases.  
 
To our knowledge, the metabolism of the four major green tea catechins 
over the first 180 minutes of incubation with phase II conjugating enzymes 
has not yet been investigated comprehensively in vitro, in human liver and 
intestine. With this gap in the data, and to produce metabolites for further 
experimental use, experiments were carried out to quantify the 
biotransformation of the major catechins using different phase II enzyme 
fractions from human liver and intestine, along with Catechol-O-methyl 
transferase (COMT) from porcine liver.  
 
4.2 – Materials and methods 
 
4.2.1 – Chemicals and reagents 
 
The following were purchased from Sigma Aldrich (Gillingham, UK): 
Dithiothreitol (DTT); Magnesium Chloride (MgCl2); S-(5′-Adenosyl)-L-
methionine (SAM); Ascorbic Acid; Catechins (EGCG, EGC, ECG, & EC); 
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Molecular biology grade H2O; 0.5 Molar Tris-HCl buffer; and Adenosine 3′-
phosphate 5′-phosphosulfate lithium salt hydrate (PAPS). ULC/MS-grade 
Acetonitrile; ULC/MS-grade methanol; Acetic acid; and Formic acid were 
purchased from Biosolve BV (Valkenswaard, the Netherlands). Purified 
Catechol-O-Methyl Transferase (COMT) from Porcine liver was 
purchased from Calzyme laboratories, Inc. (San Luis Obispo, California).  
Human liver microsomes (HLM), human intestinal microsomes (HIM), 
human liver S9 fraction, human liver cytosol, UGT reaction mix A (25 
mM UDPGA), and UGT reaction mix B (250 mM Tris-HCl buffer, 40 mM 
MgCl2, 0.125 mg/mL Alamethicin) were purchased from BD biosciences 
(Swindon, UK).  
3’-O-methyl Epicatechin (Me-EC), 4’-O-methyl Epigallocatechin (Me-
EGC), and 4’-O-methyl Epigallocatechin gallate (Me-EGCG) were 
purchased from Mitsui Norin Co. Ltd (Shizuoka, Japan). 
4.2.2 - Glucuronidation of Catechins 
 
Glucuronide assays were carried out using the manufacturer’s 
instructions (BD biosciences). Molecular biology grade H2O, UGT 
reaction mix A, UGT reaction mix B, 200 µM catechin substrate, and 
50µM ascorbic acid were combined in a total volume of 1 mL and 
warmed to 37 oC for 5 minutes. The reactions were initiated using 
differing amounts of protein depending on the cellular fractions used; 1 
mg of liver S9 fraction, 0.2 mg of human intestinal microsomes (HIM), 
and 0.5 mg of human liver microsomes (HLM). Samples of 100 µL were 
removed at 0, 10, 20, 30, 60, 90, 120, and 180 minutes and added to 
100 µL of ice-cold methanol containing 1 % ascorbic acid and acetic 
acid. After centrifugation at 10000 g for 10 minutes the supernatants 
were analysed via LC/MS.  
4.2.3 - Sulfation of Catechins 
 
Catechin sulfation was carried out using BD biosciences supplier 
manuals for liver S9 fraction and human liver cytosol. A 1 mL reaction 
mixture containing molecular biology grade H2O, 500 mM tris-HCl buffer, 
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2 mM PAPS, 200 µM catechin substrate, and 50 µM ascorbic acid was 
warmed to 37 oC. The reaction was initiated by adding either 0.5 mg of 
liver S9 protein or 0.2 mg of liver cytosolic protein. The reactions were 
terminated by adding 100 µL to an equal volume of ice-cold methanol 
containing 1 % ascorbic acid and acetic acid. After thorough vortexing 
and centrifugation the supernatants were analysed via LC/MS.   
4.2.4 – Methylation of Catechins  
 
Catechins were methylated using a similar method to Lu et al (Lu et al., 
2003b). An incubation mixture containing 10 mM tris-HCl, 1 mM 
dithiothreitol, 2 mM MgCl2, 200 µM SAM, 50 µM ascorbic acid, and 200 
µM catechin substrate was warmed to 37 oC for 5 minutes. Purified 
porcine liver COMT (500U) or human liver cytosol (0.1 mg) was added to 
the mixture to initiate the reaction. The total reaction mixture was carried 
out in a final volume of 1 mL. 100 µL aliquots were removed at 0, 10, 20, 
30, 60, 90, 120, and 180 minutes; at each time-point the reaction was 
stopped using an equal volume of 1 % ascorbic acid and acetic acid in 
ice-cold methanol. The aliquots were centrifuged and the supernatants 
were analysed for metabolites via UPLC/MS. 
4.2.5 – Data acquisition 
 
Analysis of catechins and their metabolites was carried out using mass 
spectrometric detection in negative ionisation electrospray mode on an 
Acquity UPLC system and Synapt-G2 HDMS (Waters, UK). Separation 
was acquired via an Xbridge C18 column (50mm x 4.6mm i.d., 3.5 µm) at 
a flow rate of 0.3 mL/min; and column temperature was maintained at 35 
oC. The sample injection volume was 3 µL. The sampling cone voltage 
was set at 35V; capillary voltage was set at 2.2 kV; desolvation 
temperature at 350 oC; lockspray capillary voltage was set at 3 kV; and 
source temperature at 100 oC. Leucine Enkephalin (2 ng/mL) was used 
as a reference compound in negative ion mode (m/z 554.2648).  The 
mobile phases were (A) 0.1% Formic acid in water (w/v) and (B) 0.1% 
Formic acid in acetonitrile. Initial conditions were 3% B for 1 minute, 
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increasing to 18% B at 6 minutes, staying constant at 18% B until 6.5 
minutes, back to 3% B at 6.6 minutes, and then stayed at 3% B until 8 
minutes. Accurate masses were obtained using Masslynx 4.1 software, 
with scanning across the spectrum of 50-1000 m/z. For HPLC-DAD the 
separation was acquired via an Xbridge C18 column (50mm x 4.6mm i.d., 
3.5 µm) at a flow rate of 0.3 mL/min; and column temperature was 
maintained at 35 oC. The sample injection volume was 3 µL. 
Wavelengths were measured in the range of 220 – 450 nm.  
Due to the lack of catechin metabolite standards, quantification was 
done relative to the parent catechins in the assays based on both UV-
DAD and MS intensity signals.  
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4.3– Results  
 
To analyse the metabolism of the four major catechins found in green 
tea, the studied flavan-3-ols were incubated with human phase 2 
enzymes (UGTs and Sulfotransferases) and porcine liver COMT for up 
to 180 minutes. Length of incubation was determined by the stability of 
the catechin in the enzyme mixture. Samples were removed at 0, 10, 20, 
30, 60, 90, 120, and 180 minutes, which were extracted and analysed 
via diode array ULC/MS with electrospray ionisation using a MSe 
acquisition method to quantify catechin metabolites and their parent 
compounds.  
EGCG & 4’-O-Methyl-EGCG 
 
The production of metabolites of EGCG, and its degradation by-products 
under the specific enzyme assays are shown in figures 4.1 – 4.5. 
Glucuronide, sulfate, and methylated conjugates of EGCG were observed 
in all enzyme fractions. Eleven metabolites were detected in total, two of 
which were methylated metabolites (M1 & M2), seven glucuronides (G1-
7), and two sulfates (S1 & S2). Two glucuronides, one sulfate, and one 
methylated metabolite had a later retention time than EGCG. The 
remaining seven conjugates had an earlier retention time than EGCG.  
There were no methylated metabolites detected in the presence of liver 
cytosol. COMT from porcine liver produced two methylated metabolites 
named here as M1 and M2. These were identified by their molecular 
weight which had m/z values of 471.0981 and 471.0648. Here, the mass 
error was too high (333 ppm) for proper identification and may have been 
due to instrument error. M1 appeared to be the major metabolite formed 
based on the MS/MS and UHPLC data and reached a concentration of 
23.15 ± 5.8 μM after 180 minutes, whereas M2 reached 9.27 ± 2.83 μM 
(Figure 4.1). Small amounts of an EGCG dimer (m/z 915. 1578) were also 
detected.  
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Incubation of EGCG with human liver microsomes and S9 fraction yielded 
the four glucuronide metabolites G1-4 (figure 4.2). These were identified 
as glucuronides with a molecular weight of 633. The m/z of the 
glucucronide conjugates G1 – G4 was 633.1046. The retention times in 
both fractions were identical so were assumed to be the same 
glucuronides. The EGCG dimer (m/z 915. 1578) was also detected in 
small amounts in these conditions, along with a hydroxylated glucuronide 
(m/z 649.1069) conjugate which as far as is known has not been reported 
in previous studies (figure 4.3). Liver S9 formed 42.48 ± 18.2 μM 
glucuronide conjugates after 180 minutes, and with liver microsomes 
24.91 ± 7.28 μM glucuronide conjugates were formed after 60 minutes.  
Using human intestinal microsomes, EGCG was incubated for 90 minutes 
and three glucuronides (G5-7) were formed (figure 4.4), along with 
detectable amounts of the hydroxylated glucuronide, and an EGCG dimer 
previously identified as theasinensin A (m/z 913.1345). G6 was the major 
glucuronide formed after 90 minutes, followed by G5 and G7 (figures 4.4 
and 4.5). G6 was observed to have a later retention time than EGCG and 
G5 and G7 were eluted earlier than EGCG. The maximum concentration 
of 27.5 ± 9.17 μM combined metabolites was reached at 30 minutes. After 
Figure 4.1 – formation of EGCG methylated metabolites after incubation 
with COMT from porcine liver for up to 180 minutes.  Values are expressed 
as mean ± SD, n=6. M1 and M2 are the methylated metabolites formed.  
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incubation of EGCG with intestinal and liver microsomes, the metabolites 
of EGCG reached a peak at 30 minutes, and with liver S9 the metabolites 
reached their maximal point at 120 minutes.  
  
 
 
EGCG was sulfated by liver S9 with one product formed (m/z 537.0296), 
reaching a maximum of 4.1 ± 0.813 μM at 90 minutes. The parent 
compound was stable in the presence of the S9 fraction with >90% still 
present after 180 minutes. With liver cytosol, only trace amounts of one 
EGCG sulfate (m/z 537.0296) was observed after 120 minutes.  
 
 
Figure 4.2 – formation of EGCG glucuronide conjugates using Human liver S9 fraction (A) and 
human liver microsomes (B).    Values are expressed as mean ± SD, n=6. G1 – G4 are the 
glucuronide conjugates formed during the assay.  
Figure 4.3 – m/z of the glucuronide conjugate G3 (m/z 633.1046), and detectable levels of 
the hydroxylated glucuronide (m/z 649.1069)  
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After observing the metabolism of EGCG, the methylated metabolite 4’O-
methyl-EGCG was glucuronidated and sulfated using human liver 
microsomes and cytosolic fraction.  
Incubation of 4’O-methyl-EGCG with liver cytosol yielded one sulfate 
conjugate which was detected in trace amounts after 120 minutes with an 
m/z 551.0464. To measure glucuronide formation the methylated EGCG 
was incubated with liver microsomes. After 60 minutes there were five 
conjugates present (figure 4.6). Three were glucuronide conjugates with 
molecular weights of 647.1249, 647.1267, and 647.1404. Two conjugates 
were found to be di-glucuronides (m/z 823.1612 and 823.1572, figure 4.7). 
To the best of our knowledge this is the first time di-glucuronide 
conjugates of methylated EGCG are reported. The major glucuronide 
produced was a mono-glucuronide reaching 40.36 ± 12.04 μM at 60 
minutes. The di-glucuronide conjugates were the next highest metabolites 
formed at concentrations of 22.96 ± 4.14 μM and 11.88 ± 3.76 μM at 60 
minutes. The two remaining glucuronides reached 5.8 and 4.11 μM at 60 
minutes. The five glucuronides accounted for approximately 85 % of the 
parent compound after 60 minutes.  
Figure 4.4 – formation of EGCG glucuronide conjugates using Human intestinal 
microsomes for up to 90 minutes. This time-point was lower than other metabolism 
experiments due to apparent instability of EGCG under these experimental 
conditions.  Values are expressed as mean ± SD, n=6. 
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Figure 4.5 – selected total ion current (TIC) chromatogram of EGCG and its 
glucuronide conjugates in human intestinal microsomes 
Figure 4.6 – formation of 4’-O-methyl-EGCG glucuronide conjugates using 
Human liver microsomes.  Here, 60 minutes was enough to convert 
approximately 85% of the 4’-Me-EGCG into glucuronides. Values are 
expressed as mean ± SD, n=6. 
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EGC and 4’-O-methyl-EGC 
 
Upon incubation of EGC with human liver s9 fractions and liver/intestinal 
microsomes, two metabolites were formed in each cellular fraction 
(figure 4.8). Based on retention times and m/z values, they were the 
same glucuronide conjugates so in these studies were called G8 and 
G9. In s9 fraction the two glucuronides reached a peak combined 
concentration of 7.62 ± 1.81 μM at 180 minutes, 4.93 ± 1.347 μM at 90 
minutes in liver microsomes, and 6.25 ± 2.17 μM in intestinal microsomes 
at 90 minutes. EGC degraded at a much faster rate in the presence of 
intestinal microsomes and liver microsomes, but remained stable when 
incubated with the liver s9 fraction. Small amounts of EGC-glucuronide 
dimers were also present; one dimer when incubated with liver 
microsomes (m/z 963.2071) and one dimer when incubated with intestinal 
microsomes (m/z 963.1935) (figure 4.9). 
Figure 4.7 – m/z of Methyl-EGCG glucuronides (647.1249) and di-glucuronides 
(823.1487 and 823.1612) using Human liver microsomes.  
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Figure 4.8 EGC glucuronides G8 and G9 formed in liver s9 fraction (A), liver microsomes (B), 
and intestinal microsomes (C).  Values are expressed as mean ± SD, n=6. 
Figure 4.9 - m/z of EGC glucuronide (481.0972) and its dimer (963.1935) (blue) and figure4.10 – 
4’-O-methyl-EGC-glucuronide (m/z 495.1180) and its dimer (m/z 991.2217) (green) 
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When EGC was incubated with COMT from porcine liver, one 
methylated metabolite (M3) was formed after 180 minutes with an m/z of 
319.0796 (figure 4.11). The parent compound was stable under these 
assay conditions for up to 180 minutes and thereafter rapidly decl ined, 
and produced up to 47.3 ± 5.93 μM of the single methyl metabolite at 180 
minutes. The retention time was earlier than the parent compound. As with 
EGCG, there was no methyl conjugates formed in the presence of liver 
cytosol. 
 
 
 
Two sulfated conjugates (S3 and S4) of EGC were observed in liver S9 
with molecular weights of 385.1874 and 385.1065. The mass error 
observed here made it difficult to make valid identifications of these 
metabolites. The parent EGC rapidly degraded after the 90 minute mark 
and the peak concentration of the combined sulfates reached 4.93 ± 1.098 
μM. In liver cytosol the parent compound remained stable for up to 120 
minutes, however only trace amounts of one EGC sulfate (S5) were 
present (m/z 385.0205).  
4’-O-methyl-EGC was incubated with liver cytosol and liver microsomes. 
One glucuronide (m/z 495.1180) was formed reaching a peak 
concentration of 91.04 ± 10.38 μM after 60 minutes (figure 4.12). Trace 
amounts of 4’-O-methyl-EGC glucuronide dimer were also observed (m/z 
991.2217).  After 60 minutes only 7% of the parent 4’-O-methyl-EGC was 
remaining.  
Using liver cytosol, two sulfates were observed after 180 minutes and are 
Figure 4.11 – methylation of EGC via porcine liver COMT over 180 minutes, and m/z of the 
methylated metabolite (319.0796) and dimer (639.1719).  Values are expressed as mean ± 
SD, n=6. 
 
83 
 
shown in figure 4.13 (both with m/z 399.0405). They reached a combined 
peak concentration of 47.53 ± 9.60μM after 180 minutes. Both sulfates 
eluted earlier than 4’-O-methyl-EGC. The parent 4’-O-methyl-EGC 
reached undetectable levels after 210 minutes.  
 
 
 
 
 
Figure 4.12 – Glucuronidation of 4’-O-methyl-EGC via human liver microsomes 
over 1 hour.  Values are expressed as mean ± SD, n=6. 
 
Figure 4.13 – Sulfation of 4’-O-methyl-EGC via human liver cytosolic fraction 
over 180 minutes.  Values are expressed as mean ± SD, n=6. 
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ECG 
 
There were no methylated metabolites of ECG found after incubation with 
porcine liver COMT and liver cytosol, and no sulfate conjugates observed 
in both liver S9 and cytosol incubations. No responses were observed 
when molecular ions for the methylated and sulfated conjugates were 
monitored at m/z 455 or 521Da respectively.  
ECG was extensively glucuronidated in the presence of liver s9 fraction, 
liver microsomes, and intestinal microsomes. In both liver s9 and liver 
microsomes, two glucuronide conjugates were formed and are shown in 
figure 4.14. They are identified here only as G10 and G11. Both 
metabolites in both fractions had identical retention times and m/z values 
so were presumed to be the same glucuronide conjugates. G10 had an 
earlier retention time (6.09 minutes) than ECG (6.58 minutes) and G11 
had a later retention time (6.90 minutes), the m/z for both metabolites was 
617.1173. The peak concentration of the two combined metabolites 
reached approximately 93.6 μM at 90 minutes in the s9 fraction and 86.5 
μM in liver microsomes after 120 minutes.  
 
 
 
 
Incubation of ECG with human intestinal microsomes for 180 minutes 
formed four glucuronide conjugates. The major metabolite was G11, 
identical to the one formed in liver fractions based on retention time and 
m/z. The three minor metabolites (G12-14) had earlier retention times than 
Figure 4.14 – ECG glucuronide (G10 and G11) formation from the parent ECG in liver microsomes (A), 
and liver s9 fraction (B). Values are expressed as mean ± SD, n=6. 
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the parent compound and are shown in figure 4.15. The glucuronide G10 
was not observed to be identical to any of the three metabolites G12-14 
based on retention times and m/z values. The parent ECG remained 
stable in all the UGT enzyme assays although small amounts of ECG 
dimers were observed (m/z 883.1708). 
 
 
 
EC 
 
Incubation of EC with human liver microsomes and s9 fractions yielded 
identical metabolites in both fractions (G15 and G16) with m/z 465.1058 
(figure 4.16). Both glucuronides had earlier retention times than EC. G15 
was the major metabolite in both microsomal and s9 fractions. The 
combined glucuronides reached a peak of 19.26 ± 3.94 μM in liver 
microsomes and 14.02 ± 2.81 μM in the s9 fraction. In intestinal 
microsomes, the two same glucuronides were formed and reached a 
combined peak concentration of 16.07 ± 5.7 μM. 
Two EC methylated metabolites (M4 and M5) were produced in the 
presence of COMT after 180 minutes. Both had earlier retention times 
than EC. The metabolites have m/z 303.0718 and 303.0711 Da and 
reached a combined peak concentration of 11.3 ± 2.09 μM after 180 
Figure 4.15 – ECG glucuronide formation in human intestinal microsomes (C), total ion 
chromatogram of parent ECG (A), and glucuronide conjugates (B). Values are expressed as mean ± 
SD, n=6. 
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minutes. EC remained stable in the assay up to 180 minutes. In the 
incubation with liver cytosol there were no methyl metabolites.  
 
 
 
 
Incubation of EC with liver cytosol yielded trace amounts of two sulfates 
(m/z 369.0298). Sulfation was much higher in liver s9 fraction compared to 
the cytosol as two sulfates reached a peak concentration of 7.18 ± 1.81 
μM after 180 minutes. Both metabolites had an earlier retention time than 
EC. The m/z of the sulfates were 369.0318 and 369.0298, the second of 
which was identical to the sulfate formed via the s9 fraction. Here the error 
in mass was attributed to instrument error.  In both incubations EC was 
stable for up to 180 minutes, with >70% still intact.  
3’-O-Methyl-EC was incubated with HLM and formed two glucuronides in 
small quantities (m/z 479.1230), the combination of which reached 4.08 ± 
1.14 μM after 60 minutes. One glucuronide eluted after 3’-O-Methyl-EC 
and one earlier.  
Sulfation of 3’-O-Methyl-EC yielded two sulfate conjugates (m/z of 
383.0406) with peak concentrations of 36.89 ± 6.93 μM and 17.72 ± 5.26 
μM at 180 minutes (figure 4.17). One conjugate had an earlier retention 
time than 3’-O-methyl-EC and one eluted later.  
Figure 4.16 – EC glucuronide formation in human liver microsomes and s9 fraction. Values are 
expressed as mean ± SD, n=6. 
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Figure 4.17 – 3’-O-Methyl-EC sulfate formation in human liver microsomes. Values 
are expressed as mean ± SD, n=6. 
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4.4– Discussion 
 
The aim of this study was to measure metabolite production of catechins 
using different enzyme fractions, and therefore be able to use these 
metabolites in subsequent experiments to assess their protective effects 
against mitochondrial DNA damage. The results from these metabolism 
experiments showed significant conjugation which would allow the 
conjugated mixtures to be used in further experiments. Tea catechins 
have been shown to undergo extensive conjugation in humans, mainly 
sulfates and glucuronides which are more water soluble molecules. They 
can also be rapidly methylated via the actions human placenta cytosolic 
COMT (Zhu et al., 2000, Vaidyanathan and Walle, 2002). 
To be able to understand their bioactivities in vivo, it is vital to know the 
exact bioavailability of polyphenols, and to what extent they are present 
in free or conjugated forms. These differ greatly, as EC was shown to be 
fully conjugated in the plasma, whereas EGCG was approximately 10% 
conjugated in plasma (Ullmann et al., 2003, Donovan et al., 1999). 
In all previous studies looking at either in vitro or in vivo metabolism of 
catechins; there have been no observed phase I metabolites. 
Experiments previously in rats, mice, and human in vitro systems have 
yielded only phase II conjugates (Crespy et al., 2004, Feng, 2006, 
Kuhnle et al., 2000, Lu et al., 2003a, Lu et al., 2003b, Vaidyanathan and 
Walle, 2002). Therefore in these experiments the focus was on phase II 
conjugation of catechins.  
This study was carried out to determine the extent of green tea 
catechins metabolism using phase II conjugating enzymes via in vitro 
enzyme assays at varying time-points up to 180 minutes. The fractions 
used were human liver microsomes, liver S9, liver cytosol, intestinal 
microsomes, and porcine liver COMT. The catechins and their 
conjugates were analysed via ULC/MS and ULC-DAD. Under the 
experimental conditions used, the quality of the fragmentation spectra 
was not sufficient which made it impossible to identify the flavanol ring 
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on which conjugation took place.  
 
Methylation 
For the first time, the methylation of catechins using porcine liver COMT 
was reported. Five methylated metabolites were formed in total; two 
methylated EGCG metabolites, one EGC methyl metabolite, and two 
methylated EC products. The interesting thing to note here is that they 
were all formed using porcine liver COMT and none were detected when 
catechins were incubated with human liver cytosol. In contrast to these 
results from the liver cytosol, Zhu et al showed in placental cytosol from 
human term placenta that EC was methylated to form two metabolites 
and EGC formed one methylated metabolite after incubation for 20 
minutes (Zhu et al., 2000). In another study using human COMT in liver 
microsomes, it was shown that EGCG and EGC were efficiently 
methylated to 4’’-O-methyl-EGCG and 4’-O-methyl-EGC respectively (Lu 
et al., 2003b), which showed that methylation does indeed occur in human 
hepatic fractions. Although no methyl metabolites of ECG were detected in 
either human cytosol or porcine COMT, ECG was methylated by human 
placenta cytosol, rat liver cytosol, and liver homogenates previously 
(Okushio et al., 1999, Zhu et al., 2000, Zhu et al., 2001). 200μM 
concentrations of catechins substrates were chosen in this study to 
potentially detect metabolites via diode array HPLC which may previously 
not have been detected due to being below limits of detection and 
quantification. 
 
EGC produced one methylated metabolite after 180 minutes which was 
47.3% of the parent compound. The 3’ and 4’ sites on the B ring of EGC 
were revealed as the possible sites of methylation (Lu et al., 2003b). As a 
HPLC standard for 4’O-meEGC was available and it did not correspond 
with the retention time of the methyl metabolite produced in the 
experiments, it was concluded that it was 3’-O-methylEGC.  
These findings agree with the results reported previously using rat liver 
COMT that EGC methylation was faster than EGCG (Zhu et al., 2001, Zhu 
et al., 2000). However, our experimental results disagree with the data by 
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Lu et al which showed that EGCG had a higher efficiency for methylation 
than EGC (Lu et al., 2003b). Another difference observed was the lack of 
any di-methylated EGCG. This was due to EGCG being present at high 
concentrations of 200μM, whereas the study by Lu et al showed that 4’-4’’-
diMethylEGCG was the predominant metabolite formed at concentrations 
less than 1μM. The mono-methylated EGCG was the major metabolite at 
concentrations higher than 3μM EGCG which was the case in our 
experiments. This also correlates well with in vivo data in rats which 
showed that 4’’-MeEGCG was the highest product excreted in the bile 
when the rats were given 100mg of EGCG (Kida et al., 2000).   
ECG was not methylated in our experiments by either the porcine COMT 
or the liver cytosol. However, in previous studies ECG and EC were shown 
to be methylated by rat liver homogenates/cytosol, human placental 
cytosol, and isolated preparations of rat intestine (Zhu et al., 2001, Zhu et 
al., 2000, Okushio et al., 1999, Kuhnle et al., 2000). The lack of ECG 
methyl metabolites could not be explained under our experimental 
conditions. Two EC methylated metabolites were formed after 180 
minutes. EC remained stable in these conditions for more than 180 
minutes but the metabolites formed accounted for approximately 11.3% 
after this time, indicating that EC and its methylated metabolites could 
have acted as inhibitors of porcine COMT mediated methylation.  Further 
studies are needed to assess the inhibition, if any, of EC and it methyl 
ethers against COMT especially in human systems. 
 
Glucuronidation and sulfation 
All catechins were incubated with UGT cofactors and liver/intestinal 
microsomes for up to 180 minutes to measure the amounts of 
glucuronides produced. EGCG was glucuronidated in liver microsomes 
and s9 fraction to form two glucuronide conjugates in each of the 
incubations. However in intestinal incubations there were three 
conjugates present, this could be explained by the presence of an 
intestine-specific UGT (1A8) acting on a different site of EGCG.  
In these experiments a possible hydroxylated glucuronide (m/z 649.1069) 
conjugate of EGCG was also detected. The exact structural conformation 
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is yet to be determined. This conjugate was detected in both liver and 
intestine fractions. However, due to an exact match in the retention time 
with the glucuronide and no MS/MS conformation, there is not strong 
enough evidence for the identification of this metabolite here. From the 
three fractions tested, liver s9 fractions yielded the most metabolism of 
EGCG. This difference is most likely due to the different expression of 
some UGT isoforms in the two tissues. EGCG was glucuronidated in liver 
microsomes, s9, and intestine approximately 24.9%, 42.4%, and 27.5% 
respectively. This was much higher than EGC which was 4.9%, 7.6%, and 
6.2% respectively. This was in agreement to a previous study which 
showed that UGT mediated Glucuronidation of EGCG was much higher 
than EGC (Lu et al., 2003).   
 
Crespy et al showed that rat microsomes almost completely 
glucuronidated quercetin, whereas EGCG (7.5 %) and ECG (12.2 %) were 
glucuronidated much less efficiently (Crespy et al., 2004). This is in stark 
contrast to our results using human phase II enzyme fractions, where 
EGCG was glucuronidated between 24.9 and 42.4%, and ECG was 
comprehensively glucuronidated between 86.5 - 93.6% in liver fractions, 
and 82.5% in intestinal microsomes. These gallated flavonols are the ones 
previously reported to be approximately 90% unconjugated in plasma after 
consumption in humans (Ullmann et al., 2003, Lee et al., 1995, Kotani et 
al., 2003), which cannot explain the extent of the metabolism observed in 
our experiments. The action of in vivo β-glucuronidase could explain this 
phenomenon and deconjugate the glucuronides of EGCG and ECG to 
their free forms, as they are mainly detected in plasma.  
A study looking at the glucuronidation and sulfation of EC observed that 
EC was glucuronidated to two products in rat microsomes, but was not 
glucuronidated by liver or intestinal human microsomes. It was also shown 
that EC was sulfated efficiently in human liver and intestine cytosol. They 
concluded that in the absence of any glucuronides, that sulfation was the 
major metabolic pathway of EC in human intestine and liver (Vaidyanathan 
and Walle, 2002). Based on relative quantification to their parent 
compounds, only trace amounts of sulfate conjugates were observed in 
92 
 
the liver cytosol, and approximately 7.2 % sulfates in liver s9 fractions. The 
glucuronides produced were also much more pronounced, 19.26 % in liver 
microsomes, 14.02 % in s9 fractions, and 16.6 % in intestine microsomes.  
Here it was also reported for the first time, the time-dependant sulfation 
and glucuronidation of three methylated catechin metabolites; 4’-O-
Methyl-EGCG, 4’-O-methyl-EGC, and 3’-O-Methyl-EC.  
With only trace amounts of a 4’-O-Methyl-EGCG-sulfate (m/z 551.0464), 
and the production of five glucuronides (including two di-glucuronides 
observed for the first time), it was clear that for 4’-O-Methyl-EGCG 
glucuronidation is also the main metabolism pathway. And similarly, 4’-
O-methyl-EGC produced two sulfates in liver cytosol, and reached a 
combined 47.5%. In liver microsomes, one glucuronide accounted for 91% 
of 4’-O-methyl-EGC, which showed that glucuronidation was also the 
major pathway for this metabolite.  
However, only 4.08 % of 3’-O-Methyl-EC was glucuronidated after 60 
minutes, whereas sulfation of 3’-O-Methyl-EC formed two sulfate 
conjugates accounting for 54.6 % of 3’-O-Methyl-EC at 180 minutes. Trace 
amounts of a sulphate cysteine metabolite were also detected for the first 
time. So in contrast to methylated EGC and EGCG, methylated EC was 
predominantly shown to be conjugated via the sulfate pathway. The extent 
of metabolism of these major catechins in our experiments further 
increases the likelihood that some, if not many, of the in vivo bioactivities 
of green tea catechins may in fact be wielded by their methylated or 
sulfate/glucuronide counterparts.  
From what was observed in terms of formation of glucuronides in liver 
and intestine, it would also be important to see the amounts of methyl-
glucuronides, methyl-sulfates, and if any sulfate-glucuronides are formed 
if the enzymes and essential cofactors are pooled together (or just use 
an S9 fraction to see if there any sulfated glucuronides formed).  
Further studies are needed and should incorporate NMR data to 
elucidate exact structures of the catechin metabolites, and possible 
dimer/trimers formed. The metabolites formed in our studies show the 
breadth of phase II metabolism in human intestine and liver, and should 
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be taken into account in future studies which look at the effects of tea 
consumption on health effects in humans. The production or availability 
of metabolite standards should also greatly help with exact 
quantifications of metabolites produced. Future studies should consider 
looking at the combined pharmacological activities of these metabolites 
exactly in the amounts they appear in human plasma which will give a 
better indication of their effects in vivo. The concentrations of the 
metabolites used in future studies should remain physiologically relevant 
which will aid in clearing up any uncertainties which stem from using 
pharmacological concentrations in many in vitro studies.   
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5- Protective effects of green tea catechins and their 
metabolites against mitochondrial DNA damage in 
intestinal cell lines 
 
Abstract 
 
Background: Mitochondria are the cells main source of ROS production 
via the electron transport chain. Mitochondrial DNA is close to this site, 
which makes it susceptible to damage via oxidative stress. MtDNA also 
possesses less efficient DNA repair machinery than nuclear DNA, and 
lacks protective histones. It was hypothesised that physiological 
concentrations of green tea catechins and their metabolites could protect 
mtDNA against H2O2 induced damage in intestinal cells. Methods: TC7 
and Caco-2 cells were incubated with 50 – 25 µM catechins initially. 
Thereafter, physiological concentrations of catechins and metabolites 
were incubated for 4 hours with intestinal cells before the cells were 
stressed for 24 hours with H2O2. Cellular DNA was extracted and analysed 
via RT-PCR to measure the difference in damage of a long fragment vs a 
short fragment. Results were compared to a H2O2 treated control. 
Results: Higher concentrations of catechins > 25 µM did not protect 
against mtDNA damage in intestinal cells. When concentrations were 
reduced to < 5 µM, significant protection against mtDNA damage was 
observed with all four catechins. Surprisingly, significant effects were also 
seen at concentrations less than 1 µM. Metabolites of catechins had less 
bioactivity compared to their parent compounds when protecting against 
mtDNA damage. Conclusions:  These results show potent effects of 
catechins and their metabolites in tissues with high exposure to them after 
ingestion. Further studies are needed to determine exact mechanisms of 
action, and potential role of other flavonoids in protecting mtDNA from 
oxidative damage.  
 
100 
 
5.1– Introduction 
 
 
Mitochondria are the predominant cellular organelles for producing ATP 
and regulation of cellular metabolism, and are therefore referred to as the 
‘powerhouse’ of the cell.  They are located near the endoplasmic 
reticulum, and play roles in apoptosis, lipid biosynthesis, and protein 
production (Raturi and Simmen, 2013, Riemer et al., 2009, Sinha et al., 
2013, Vance, 1990). Mitochondria account for approximately 90 % 
consumption of the oxygen used by aerobic cells, and ~1-2 % of this 
oxygen forms reactive oxygen species (ROS) which can subjugate 
intracellular antioxidant defence systems (Boveris and Chance, 1973). 
These ROS molecules can cause oxidative damage to the mitochondrial 
DNA (mtDNA), lipids, and proteins as they are continuously produced in 
the mitochondrial respiratory chain (Chance et al., 1979). This can lead to 
increased accumulation of intracellular damage to these macromolecules, 
along with a decreased antioxidative capacity, and therefore can play a 
major role in the ageing process.  
In contrast to other macromolecules, point mutations and deletions can 
occur when mtDNA is damaged. These can accumulate and transmit 
through replication, and therefore deteriorate the integrity of the DNA over 
the course of multiple replications (Fleming et al., 1982, Miquel et al., 
1983). This characteristic is what has made mtDNA damage a core 
discussion of ageing. 
Thirty-seven genes, including 13 polypeptides (all components of the 
oxidative phosphorylation system), 22 tRNAs, and 2 rRNAs are encoded in 
mtDNA molecules (Filosto et al., 2011, Mancuso et al., 2009). As these 
genes code for various mitochondrial proteins and many subunits of the 
electron transport chain (ETC), mtDNA must remain intact and free from 
mutations and damage to ensure the normal functioning of the 
mitochondria (Bohr, 2002). Oxidative phosphorylation (OXPHOS) 
deficiency and mitochondrial diseases can occur if proper ETC function is 
not maintained, via the increase in ROS production (Melov et al., 1998, 
Wallace, 2002).  
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MtDNA has been reported to be 10- 20- fold more susceptible to damage 
when compared to nuclear DNA, with the damage being more extensive 
and lingering for a longer period of time (Stowe and Camara, 2009, Yakes 
and Van Houten, 1997). This increased susceptibility to damage of mtDNA 
is attributed to its close proximity to the ROS-rich location of the ETC, and 
its lack of protective histones which are prevalent in nuclear DNA. MtDNA 
also has an increased chance of mutations in coding regions owing to the 
fact that there very few noncoding regions (Anderson et al., 1981, Santos 
et al., 2012).  
Polyphenols and mitochondria 
Several epidemiological studies have suggested that dietary polyphenols 
can reduce the risk of various chronic conditions such as 
neurodegenerative diseases, some cancers, and cardiovascular disease 
(Checkoway et al., 2002, Kuriyama et al., 2006). After treatment with 
micromolar concentrations of Quercetin (10 – 50 μM), caco-2 cells were 
found to be protected against oxidative stress (Carrasco-Pozo et al., 
2012), and accumulate in mitochondria (Fiorani et al., 2010). 
Indomethacin induced mitochondrial dysfunction was also significantly 
reduced in caco-2 cells by resveratrol (0.1 mg/ml) and rutin (1 mg/ml) 
(Carrasco-Pozo et al., 2012). Using C2C12 and mice skeletal myotubes, 
it was shown that physiological concentrations of resveratrol had a 
positive effect on mitochondrial function, whereas higher concentrations 
(100 μM) led to the loss of mitochondrial membrane potential (Higashida 
et al., 2013). Resveratrol was also shown to improve mitochondrial 
activity and biogenesis in other studies (Murase et al., 2009, Hart et al., 
2013, Um et al., 2010, Menzies et al., 2013). Resveratrol was shown to 
decrease the production of superoxide anions, and total ROS levels 
particularly in mitochondria. It appeared to achieve this by inhibiting lipid 
peroxidation, inducing expression of radical scavenging enzymes such 
as manganese containing superoxide dismutase, and replenished 
glutathione levels thereby increasing the level of antioxidant capacity 
(Leonard et al., 2003, Li et al., 2013). A previous study found that 
physiological concentrations of EGCG protected against ROS-induced 
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chromosomal damage in WIL2-NS cells (Sugisawa and Umegaki, 2002).  
In view of the importance of maintaining mitochondrial integrity, and 
prevalence of consumption of green tea, it was the aim of the present 
study to determine the in vitro protective effects of green tea catechins 
and their metabolites against H2O2 induced mitochondrial DNA damage 
in human intestinal cell lines. The protective effect of green tea 
catechins against mtDNA damage in intestinal cells has not been 
explored previously. It was hypothesised that catechins would reduce 
the H2O2 induced mtDNA damage in intestinal cells as these cells are 
directly exposed to catechins after ingestion of green tea.  
5.2– Materials and methods 
 
5.2.1 - Chemicals and reagents 
 
The following were purchased from Sigma Aldrich (Gillingham, UK): 
Epigallocatechin-3-gallate (EGCG); Epigallocatechin (EGC); Epicatchin-
3-gallate (ECG); Epicatechin (Fleming et al.); Ascorbic acid; and 
Hydrogen peroxide. 3’-O-methyl Epicatechin (Me-EC), 4’-O-methyl 
Epigallocatechin (Me-EGC), and 4’-O-methyl Epigallocatechin gallate 
(Me-EGCG) were purchased from Mitsui Norin Co. Ltd (Shizuoka, 
Japan). Methylated, glucuronidated, and sulfated metabolite mixtures 
were obtained from enzyme assays (detailed in chapter 4). The following 
were acquired from Life Technologies (Invitrogen): Dulbecco’s modified 
Eagle’s medium (DMEM); foetal Bovine serum (FBS); 
Penicillin/Streptomycin (1:1); Trypsin-EDTA; non-essential amino acids 
(NEAA); and L-Glutamine. SYBR-green was obtained from Applied 
Biosystems (Life Technologies, Netherlands). Primers for Mitochondrial 
DNA fragments were purchased from Eurofins Genomics (Ebersberg, 
Germany). The Genomic DNA purification kit was purchased from 
ThermoScientific (Leicestershire, UK).  
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5.2.2– Cell culture 
 
Caco-2 cells (human colon adenocarcinoma) obtained from ATCC and 
Caco-2/TC7 clones were grown routinely in Dulbecco’s modified Eagle’s 
medium DMEM, supplemented with 10% Foetal bovine serum (FBS), 
2mM Glutamine, 1% pen/strep, and 1% non-essential amino acids. All 
cells were cultured and maintained in 75cm2 flasks, with the environment 
controlled at 37oC and 5% CO2. The cell medium was changed every 2 
days (3 times per week), and cells were sub-cultured at 80% confluence. 
For the measurement of mitochondrial DNA (mtDNA) damage; 12-well 
plates were used and were incubated with Catechins at varying 
concentrations. Cells were seeded onto 12-well plates at 5 x 103 cells 
per well. Ascorbic acid was co-incubated at 5µM. Experiments were 
carried out 4 days post-seeding when cells were 100% confluent. Caco-
2 cells at passage 6-19 were used, and TC7 cells were used at passage 
68-79. 
5.2.3– MtDNA damage assessment 
 
Both Caco-2 and TC7 cells were cultured in 12-well plates to 100% 
confluence. They were then washed twice with warm PBS, and 
incubated with different concentrations of Catechins and metabolites for 
varying lengths of time. In the case of metabolite mixtures from enzyme 
assays the same concentration of parent compound was added along 
with the metabolites, to account for the effect of the remaining parent 
compound in the enzyme assays at the termination point. Catechins and 
metabolites were removed by washing the cells again twice with PBS, 
and then inducing mitochondrial DNA (mtDNA) damage by chronic 
exposure of the cells to 500 μM H2O2 for 24 hours (Caco-2 cells) and 
500 μM H2O2 for 48 hours (TC7 cells). H2O2 concentration and length of 
exposure was determined via its ability to induce a statistically significant 
amount of mtDNA damage as well as keeping cell viability >80 %, which 
was different to H400 cells. These were measured with various dose-
response experiments and MTS assay. The concentrations of H2O2 used 
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were 50, 100, 250, and 500 μM for 16, 24, and 48 hours.  
The H2O2 was removed and genomic DNA was extracted using a 
cultured mammalian cells Genomic DNA purification protocol 
(ThermoScientific). The total assay volumes for rt-PCR was 25 µL, which 
included 40 ng of extracted DNA, forward and reverse primers, and a 
SYBR green PCR master mix. The 7500 RT-PCR sequence detection 
software (version 1.3.1, Applied Biosystems) and Applied Biosystems 
7500 RT-PCR machine was used for the assays. Mitochondrial DNA 
damage was expressed as a Ct value (cycles to threshold) fold 
difference of a long (972bp) mtDNA fragment in relation to a short (83bp) 
fragment mtDNA primer. The Ct value is inversely proportional to the 
quantity of DNA and is measured logarithmically as the amount of DNA 
is theoretically doubled in every PCR cycle.  
The primers used were as follows:  
Long fragment (972bp) – AL4_F (forward): 5’-
CTGTTCTTTCATGGGGAAGC-3’ AS1_R (reverse): 5’-
AAAGTGCATACCGCCAAAAG-3’ 
Short fragment (83bp) – IS1 (forward): 5’-
GATTTGGGTACCACCCAAGTATTG-3’  
IS2 (reverse): 5’-AATATTCATGGTGGCTGGCAGTA-3’.  
The PCR program for the long fragment amplification was as follows: 1 
cycle at 95°C for 10 minutes, 40 cycles at 95°C for 15 seconds, 60°C for 
15 seconds, 72°C for 55 seconds. For the short fragment amplification 
the PCR program was: 1 cycle at 95°C for 10 minutes, 40 cycles at 95°C 
for 15 seconds, 60°C for 15 seconds, 72°C for 15 seconds. 
5.2.4– Statistical analysis 
 
All data were analysed using GraphPad Prism 5.03 (GraphPad software 
Inc. La Jolla, California). Values were expressed mean ± SEM (n=3) and 
represented as a difference in Ct values in comparison to untreated 
controls. A one-way ANOVA with Newman-Keuls multiple comparison 
tests were carried out to measure statistical significance. Differences were 
considered significant if p values were <0.05.  
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5.3 – Results 
 
– TC7 cells 
 
The concentration of H2O2 and length of exposure which induced 
significant mtDNA damage and kept cell viability ≥ 80% was determined 
to be 500 μM for 48 hours. As the H2O2 was prone to degradation in cell 
culture, it was replenished at 24 hours with fresh medium and H2O2. 
In all experiments, Tiron offered between 88.7 and 96.8 % protection 
against mtDNA damage. 2mM was used as it had previously been 
shown to be almost completely protective against mtDNA damage, and 
in our experiments there was also no significant reduction in cell viability 
at this concentration.   
Catechins added at 50 and 25 μM before exposure to H2O2 did not 
protect against mtDNA damage, and in some cases increased the 
amount of mtDNA damage slightly (Figure 5.9). In light of this possible 
pro-oxidant effect of catechins at these high concentrations, lower 
concentrations were then used (<10 μM).  
 
Catechins show significant protection against mtDNA damage at 
physiological concentrations  
 
 
10 μM, 5 μM, and 1 μM of catechins were first incubated with TC7 cells 
for 18 hours to determine if there was any protective effect against 
mtDNA damage. The results are shown in figure 5.1. At 18 hours 
incubation; EGCG and ECG had significant protection across all three 
concentrations, whereas EGC was not significantly protective at 1 μM, 
and EC only conveyed significant protection at 10 μM. EGCG and EC 
showed a concentration dependent increase in protection at 18 hours of 
incubation. With ECG and EGC, 5 μM showed greater protection than 10 
μM (figure 5.1). With significant protection observed after incubation with 
catechins at 18 hours, the time-point was reduced to a more 
physiologically representative 4 hours.  
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The data of the individual catechins at physiological concentrations at 4 
hours are shown in figures 5.2 and 5.3. Tiron was chosen as the control 
which offered almost complete protection against H2O2 induced mtDNA 
damage as shown in a previous study Oyewole et al. (2014). At 
incubation of 4 hours with individual catechins, concentrations of 1 μM 
afforded significant protection against H2O2 induced damage; EGCG – 
69.2±15.1%, EGC – 51±22.4 %, ECG – 74.26± 22.6 %, and EC – 
61.49±19.28 %. At 0.5 μM, EC was the only catechin which according to 
the statistical Newman-Keuls comparison test did not show a significant 
protective effect.  EGCG, EGC, and ECG at 0.5 μM reduced mtDNA 
damage by approximately 42.6, 41.6, and 39.7 % respectively (figures 
5.2 and 5.3).  
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Figure 5.1 – analysis of mtDNA damage after incubation of catechins with TC7 cells for 18 hours. 
Tiron was used as a positive control in all experiments. Data for EGCG (A), EGC (B), ECG (C), and 
EC (D) are shown and expressed as the mean value ± SD (n=3). *p<0.5, **p<0.01, ***p<0.001. There 
were statistically significant differences observed between 10 µM and 1 µM EGCG, and between ECG 
at 5 µM and 1 µM (*p<0.5). 
107 
 
Metabolites of catechins protect against mtDNA damage in TC7 cells 
 
Two metabolites/ metabolite mixtures were also tested in TC7 cells for 
their comparative bioactivities in relation to their unconjugated parent 
compounds. The results are shown in figure 5.4 for these metabolites. 
4’O-methyl-EGCG was obtained and used in the mtDNA assay as 
purified metabolite, whereas the glucuronides for ECG were a mixture of 
two glucuronides obtained from the UGT enzyme assay (liver s9 
fraction). The UGT was stopped at 120 minutes when the approximate 
concentration of the two combined glucuronides was 90% of the starting 
parent compound.  
In this experiment EGCG and ECG had a protective effect of 68.5 and 
71.8 % respectively which was very similar to our previous experiment at 
4 hours incubation. 4’O-methyl-EGCG showed a significant 37.8 % 
reduction in mtDNA damage and the mixture of ECG glucuronides also 
significantly protected mtDNA by 44.4 %. These results showed that the 
parent compounds were more bioactive in this experiment as they 
conferred higher mtDNA protection; in the case of EGCG the difference 
in bioactivity was significant (* p < 0.05). EGCG was 30.7 % more 
bioactive against mtDNA damage than 4’O-methyl-EGCG, and the ECG 
glucuronides were 27.4 % less effective than the parent ECG in 
protecting mtDNA against H2O2 induced damage.  
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Figure 5.2 – Protective effects of physiological concentrations of EGCG and EGC against 
mtDNA damage in TC7 cells for 4 hours. Treatments are in comparison to the non-treated 
H2O2 exposed cells (H2O2 500 μM). *P <0.05, **P <0.01, ***P <0.001).  
Figure 5.3 – Incubation of physiological concentrations of ECG and EC with TC7 
cells for 4 hours. Treatment with 2 mM Tiron offers almost complete protection 
against mtDNA damage whereas the physiological concentrations of catechins offer 
less – but significant – protection. Of the four catechins, only 0.5 μM of EC did not 
seem to offer any significant protection against mtDNA damage 
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5.1.1 – Caco-2 cells 
 
 
The remaining experiments on catechins, their purified metabolites, and 
conjugated catechins obtained from enzyme assay mixtures for their 
protective effects against mtDNA damage were carried out in Caco-2 
cells. In these experiments 5 μM concentrations for all catechins and 
conjugates were used as the aim was to only compare the differences in 
bioactivity between parent catechins and metabolites, as protective 
effects had already been observed in intestinal TC7 cells. The time of 
catechin/metabolite incubation remained the same at 4 hours.  
 
EGCG and its metabolites significantly reduce H2O2 induced mtDNA 
damage in caco-2 cells 
 
The results in figure 5.5 show that incubation of EGCG and its 
metabolites confer statistically significant protection against mtDNA 
Figure 5.4 – protective effect of catechin parent compounds in comparison to 
their conjugated counterparts. 0.1 μM of ECG was included to account for 
approximately the same concentration found in the enzyme mixture 
containing the two ECG glucuronides. The results show that the 
metabolites are physiologically bioactive; however, they were significantly 
less bioactive than their parent counterparts.  
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damage in caco-2 cells, P <0.05 (figure 5.5). All compounds were 
incubated at the physiological time-point of 4 hours. Interestingly, the 
methylated form of EGCG showed a 5.7 % increase in protection against 
mtDNA damage than the parent EGCG at 5 μM although this was not 
statistically significant. This observation was in stark contrast to the 
results in TC7 cells at 1 μM where there was a significant 30.7 % 
reduction in protection of the methylated EGCG compared to the parent 
compound (EGCG 68.5 % vs 4’O-methyl-EGCG 37.8%).  
 
4’-O-methyl-EGCG was incubated with human liver microsomes to yield 
85% glucuronide conjugates after 60 minutes (chapter 4). After 60 
minutes approximately 9 % of the original 4’-O-methyl-EGCG was still 
present. To counter this effect when comparing their mtDNA protective 
capabilities, 0.53 μM of 4’-O-methyl-EGCG was analysed alongside the 
glucuronides to account for its effects as it was also present in the 
enzyme assay mixture at approximately this concentration. This was 
done for EGCG also which metabolised to glucuronides, where after 180 
minutes approximately 3.5 % of EGCG was still remaining so 0.41 μM of 
EGCG was analysed for comparison with the enzyme mixture. Even at 
0.41 μM, EGCG showed a statistically significant protection against 
mtDNA damage, and the 5 μM EGCG-glucuronide enzyme assay 
mixture which also contained 0.41 μM EGCG showed a visibly greater 
protective effect, indicating that the glucuronides had a protective effect 
against mtDNA damage. The results are shown in figure 5.6. It was also 
observed that 0.53 μM 4’-O-methyl-EGCG did not have a statistically 
significant protective effect against mtDNA damage, indicating that the 
protective effect observed with 5 μM 4’-O-methyl-EGCG-glucuronides 
was due to the glucuronide conjugates.  
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Figure 5.5 – Protective effects of EGCG, its methylated metabolite 4’-O-
methyl-EGCG, and their glucuronide conjugates in caco-2 cells. The 
methylated EGCG was used as a pure compound, whereas the 
glucuronides were obtained from enzyme assay mixtures. *P <0.05, **P 
<0.01.  
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EGC and its metabolites significantly reduce H2O2 induced mtDNA 
damage in caco-2 cells 
EGC, 4’-O-methyl-EGC, 4’-O-methyl-EGC-sulfates, and 4’-O-methyl-
EGC-glucuronide were added at 5 μM to Caco-2 cells. The sulfates and 
glucuronide were removed from UGT and SULT enzyme assays carried 
out previously and the 4’-O-methyl-EGC was the purified compound. The 
glucuronide assay was continued for 90 minutes to allow for the 
disappearance of the ‘parent’ methylated compound, and the SULT 
assay was carried out for 210 minutes to reduce the methylated EGC to 
be reduced to trace amounts. The results are shown in figure 5.7.  
EGC showed a reduction of mtDNA damage by 45.3 %, compared to 
29.5 % for 4’-O-methyl-EGC, 20.8 % for 4’-O-methyl-EGC-glucuronide, 
and 12.9 % for 4’-O-methyl-EGC-sulfates. Although the methylated 
metabolite and sulfate/glucuronide conjugates showed significant 
Figure 5.6 – Protective effects of comparative amounts of parent compounds EGCG and 
its methylated metabolite 4’-O-methyl-EGCG in enzyme assays. 0.41 and 0.53 μM were 
selected because they were the remaining concentrations of parent compound in the 
enzyme assays at the selected time points from where the metabolites were used. The 
results show that the parent compound and metabolites were equally effective but 
these differences were not statistically significant.  
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mtDNA protection, they were significantly reduced when compared to 
the parent EGC. The difference is summarised in table 5.1 where the 
statistically significant treatments are compared to each other. 
   
Newman-Keuls Multiple Comparison Test % difference P  
EGC vs 4'-O-Me-EGC-Sulfates 32.4 0.001 
EGC vs 4'-O-Me-EGC-Glucuronide 24.5 0.01 
EGC vs 4'-O-Me-EGC 15.8 0.05 
4'-O-Me-EGC vs 4'-O-Me-EGC-Sulfates 16.6 0.05 
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Figure 5.7 – Protective effects of EGC, its methylated metabolite 4’-O-methyl-EGC, 
and its glucuronide/sulfate conjugates in caco-2 cells. The methylated EGC was 
used as a pure compound, whereas the glucuronide/sulfates were obtained from 
enzyme assay mixtures. *P <0.05, **P <0.01, ***P <0.001. n=3 and data are 
expressed as means ± SD. 
 
Table 5.1 – Direct comparisons of different EGC treatments of Caco-2 cells that were 
statistically significant. The significance in varying protective effects against mtDNA 
damage is indicated by the P values. *P <0.05, **P <0.01, ***P <0.001. Data were 
analysed using one way ANOVA with Newman-Keuls multiple comparison test.  
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The results in figure 5.7 are shown in order of the compounds protective 
effect. They show that as the extent of conjugation is increased, the 
protective effect against H2O2 induced mtDNA damage is decreased.  
EC and its metabolites significantly reduce H2O2 induced mtDNA 
damage in caco-2 cells 
EC and its metabolites were incubated with caco-2 cells in the same 
concentrations as EGC. 3’-O-methyl-EC was metabolised in the SULT 
assay 210 minutes so that the original metabolite was reduced to 
approximately 6%. For this reason 0.55 μM of 3’-O-methyl-EC was also 
tested to compensate for this amount in the sulphate conjugate mixture 
(Figure 5.8). EC when added to caco-2 cells offered a 53.6 % protective 
effect, but its metabolites were significantly lower in protecting mtDNA 
against H2O2 induced damage. 
 
 
Figure 5.8 – Protective effects of EC, its methylated metabolite 3’-O-methyl-EGC, and its sulfate 
conjugates in caco-2 cells. The methylated EC was used as a pure compound, whereas the sulfates 
were obtained from enzyme assay mixtures. 0.55 μM 3’-o-methyl-EC is used here for comparison with 
the sulfate mixture as this mixture contained approx. the same concentration of 3’-o-methyl-EC. *P 
<0.05, **P <0.01, ***P <0.001. N=3 and data are expressed as means ± SD. 
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Although lower than the parent EC, the methylated compound 3’-O-
methyl-EC still conferred a significant 32.6 % protection, and the mixture 
of 3’-O-methyl-EC-sulfates reduced mtDNA damage by 20.3 %.  
Because the sulfate mixture contained approximately 0.55 μM of 3’-O-
methyl-EC, this concentration was also measured for its protective 
effect. It reduced mtDNA damage by 11.1 % but this was not statistically 
significant according to the statistical test employed.  
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Figure 5.9 – Protective effects of EGCG, EGC, ECG, and EC at 50 and 25 μM in TC7 
cells.  N=3 and data are expressed as means ± SD. No significant protection was 
observed at these concentrations. EGCG and EGC at 50 μM had slightly higher 
amounts of mtDNA damage than the H2O2 treated cells.  
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5.4– Discussion 
 
The current in vitro studies aimed to examine for the first time, green tea 
polyphenols and their metabolites for their ability to protect mtDNA 
against H2O2 induced damage in human intestinal Caco-2 and TC7 cell 
lines. It was shown that physiological concentrations (less than 5 µM) 
conferred significant protection against mtDNA damage with all four 
catechins. It was shown that metabolites of catechins had less bioactivity 
compared to their parent compounds when protecting against mtDNA 
damage. 
The constant formation of ROS by the mitochondrial electron transport 
chain during the life of the cell leads to an accumulating oxidative stress 
on mitochondrial function, and is considered a leading factor in cellular 
ageing. Lipids, proteins, and mtDNA are known to undergo oxidative 
damage throughout ageing via these oxidative stressors (Shigenaga et al., 
1994, Benzi and Moretti, 1995, Sastre et al., 1998). This is thought to be 
the case when increased ROS production in the mitochondria and faulty 
antioxidant defence systems results in redox imbalances. Approximately 
95 % of the mtDNA molecule is coding regions compared to nuclear DNA 
which is only 3 %, as mtDNA does not contain introns. Hence any damage 
to mtDNA is expected to have negative effects on a coding region (Shadel 
and Clayton, 1997).  
In the last couple of decades there has been an increasing interest in the 
effects of dietary polyphenol consumption and reducing the risk of 
developing chronic diseases (Kris-Etherton et al., 2002, Visioli et al., 
2011). These health effects have often been attributed to the ability of 
polyphenols to act as efficient ROS quenching bioactives, however there 
are large differences in the concentrations that are possible in plasma after 
oral consumption and the concentrations used in vitro (Perron and 
Brumaghim, 2009, Sang et al., 2005). This raises questions regarding the 
possibility that polyphenols act mainly through ROS scavenging 
mechanisms in vivo. Even so, lower concentrations of polyphenols are 
generally required to exert their effects via different antioxidant 
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mechanisms (Fraga et al., 2010) such as; increasing the 
expression/activity of endogenous antioxidant enzymes, and increasing 
ROS scavenging enzymes (Lagoa et al., 2011, Tsuji et al., 2013). Recently 
it been reported that these mechanisms may coincide at different 
concentrations in different tissues and cellular compartments, and 
importantly, also in the mitochondria (Schaffer et al., 2012, Visioli et al., 
2011). Polyphenols have been shown to control mitochondrial ATP 
synthesis and its electron transport chain (Carrasco-Pozo et al., 2011), 
mitochondrial membrane potential (Santos et al., 1998), and induce 
sirtuins to modulate mitochondrial biogenesis (Chung et al., 2010). 
Curcumin (8 µM) and resveratrol (100 µM)  were shown to protect mtDNA 
against H2O2 induced damage by 16 and 22 % respectively, with 8 and 22 
% protection being observed in response to UVA induced mtDNA damage 
(Oyewole et al., 2014).  
The study carried out by Higashida et al showed that pharmacological 
concentrations of resveratrol were cytotoxic in C2C12 cells (in this case 
greater than 50 μM). Interestingly, they ‘adapted’ the cells by exposing 
them intermittently for 6 hours to mild stress inducing concentrations of 
resveratrol (20 μM), leading to increased mitochondrial biogenesis. This 
indicated that the mild stress stimulated long term increases in oxidative 
capacity (Higashida et al., 2013).  
Polyphenols undergo significant metabolism after ingestion to their 
glucuronide and sulfate conjugates, as well as methylated metabolites 
(Feng, 2006). The reducing hydroxyl groups on the phenol structure are 
the targets of glucuronidation and sulfation, and this may lead to significant 
reduction in bioactivity as these are the main phenolic groups to which 
antioxidant properties are attributed (Piazzon et al., 2012). Sulfation and 
glucuronide conjugation make molecules more hydrophilic, which can in 
turn affect their mode/site of activity (Manach et al., 2004). Due to the lack 
of analytical and purified polyphenol metabolites, there are very few 
studies which have been able to determine the bioactivities of these 
conjugates in relation to their parent compounds.  
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This study helped to determine the in vitro bioactivities of purified 
methylated green tea metabolites, and mixtures of enzyme assay 
conjugates (glucuronides, sulfates, methyl-glucuronides, and methyl-
sulfates) against mtDNA damage in human intestinal cells.  
TC7 cells were used to determine concentrations of H2O2 deemed to 
induce significant amounts of mtDNA damage over time-points longer than 
18 hours. This was to assess the protective effects of green tea catechins 
against chronic exposure to damage inducing stressors. Higher 
concentrations of catechins (50 and 25 µM) produced expected results of 
slightly increased or unchanged mtDNA damage compared to H2O2 
treated controls. This is because at higher concentrations of >10 µM, 
polyphenols can behave as pro-oxidants in vitro and produce extra H2O2 
(Halliwell, 2008). Those results were consistent with our findings of 
catechins at concentrations greater than 25 µM. Concentrations this high 
are not attainable in vivo anyway, so there would be no excess mtDNA 
damage in vivo just by consuming green tea. Of all the 
catechins/metabolites tested at concentrations below 5 µM, none were 
found to be cytotoxic or to produce any mtDNA damage.  
Tiron conferred almost complete protection (88.7 - 96.8 %) against 
mtDNA damage in intestine cells. This was in agreement with Oyewole 
et al which showed that tiron was able to permeate the mitochondrial 
membrane and offer 100 % protection against both H2O2 and UVA 
induced mtDNA damage in cultured skin fibroblasts (Oyewole et al., 
2014).  
After incubating catechins with intestinal cells for 18 hours to determine 
if they had any protective effects against mtDNA damage (figure 5.1), 
the time-point was reduced to 4 hours to give physiologically 
representative conditions to catechin exposure, and concentrations of 
catechins were also reduced to 1 and 0.5 µM to represent physiological 
concentrations. In light of previous studies on green tea catechins and 
their significant bioactivities (Rosen, 2012), some protection against 
mtDNA damage was expected. Catechins offered much higher 
protection than expected (51 – 74.26 %) at physiological concentrations, 
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and with such a difference in concentration of H2O2 (500 µM) and 
catechins (0.5 – 1 µM) it was unlikely that this protective effect was due 
solely to the antioxidant properties of catechins. EGCG, EGC, and ECG 
at 0.5 μM had a protective effect of 42.6, 41.6, and 39.7 % respectively, 
whereas EC did not show significant protective effects at 0.5 μM. This 
was unexpected as EC is shown to be more stable in in vitro conditions 
(Zhu et al., 1997).These results agreed with a study by Sugisawa and 
Umegaki who showed that physiological concentrations of EGCG 
prevented ROS induced chromosomal damage in WIL2-NS cells 
(Sugisawa and Umegaki, 2002). They showed that damage was less in 
cells treated with 0.3 µM of EGCG than 1 - 10 µM despite the fact that 
there was no H2O2 produced at up to 10 µM EGCG.  
The results from our study suggest that catechins have no negative 
mitochondrial effects in the gastrointestinal tract (intestinal cells in this 
study, and oral cavity in chapter 3) at physiological concentrations. The 
mtDNA protective effect of the catechins at physiological concentrations 
was shown to be occurring inside the cells, as before the cells were 
exposed to H2O2, they were washed twice to remove all extracellular 
catechins present. However what is worthy of note here is that catechins 
may have been adsorbed or trapped onto the surface of the cellular 
membranes and therefore eliciting some protective effects via this action. 
The second aim of this study was to ascertain whether or not metabolites 
of catechins had similar, greater, or reduced capacities to protect mtDNA 
from damage in relation to their parent compounds.  
These results from the metabolite experiments showed that the parent 
compounds were more bioactive across the board with one exception; 
EGCG at 1 µM was significantly (30.7 %) more effective than 1 µM 4’O-
methyl-EGCG in protecting mtDNA against H2O2 induced damage in 
TC7 cells. However in caco-2 cells at 5 µM concentrations, the parent 
EGCG showed a 5.7 % decrease in protection when compared to 4’O-
methyl-EGCG. This difference between the two concentrations could be 
explained possibly due to the stability of 1 µM EGCG being lower than 5 
µM under cell culture conditions. EGCG and 4’O-methyl-EGCG were 
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glucuronidated using human liver microsomes and their resulting 
glucuronide conjugates were also analysed for their protection against 
mtDNA damage. EGCG glucuronides were significantly effective, yet 
less than EGCG at protecting mtDNA from damage. Interestingly, the 
4’O-methyl-EGCG-glucuronide was less effective than the EGCG-
glucuronides. This was unexpected, as usually more conjugation is 
related to lower bioactivities (Cren-Olive et al., 2003, Duenas et al., 
2010, Lu et al., 2003). However this is not always the case, as a study 
previously also showed that conjugation improved the bioactivity of 
catechin metabolites in human aortic endothelial cells, inhibiting 
monocyte adhesion to interleukin 1 whereas the parent catechin did not 
(Koga and Meydani, 2001). Our results from EGCG glucuronides 
bioactivity were in agreement with the study of Lu et al, who showed that 
glucuronides of EGCG and EGC retained siginificant bioactivities and 
effectively reduced the release of arachidonic acid from HT-29 human 
colon cancer cells (Lu et al., 2003), however, they used purified 
metabolites whereas in our study enzyme assay mixtures were used.  
Because there were small concentrations of parent compounds 
remaining at the termination time-point of the enzyme assays, a relative 
proportion of the parent compound was also tested for protection against 
mtDNA damage (figure 5.6). Here, 0.41 µM of the parent EGCG showed 
significant reduction in damage, whereas the 4’O-methyl-EGCG at 0.53 
µM failed to significantly reduce mtDNA damage, which indicated that the 
protective effects could indeed be attributed to the conjugates.  
The two ECG glucuronides formed in the glucuronide enzyme assay 
were 27.4 % less effective than the parent ECG in protecting mtDNA 
against H2O2 induced damage. 0.1 µM of parent ECG was also analysed 
in tandem to ensure the protective effects were not observed due to the 
ECG remaining at the end point of the ECG glucuronidation assay. Again, 
even though bioactivity of the ECG-glucuronides was significantly reduced 
as compared to ECG, the protective effect against mtDNA damage was 
still visibly significant. The lower activities of the catechin metabolites could 
be explained by both their reduced antioxidant capacity, and interactions 
with cell membrane transporters which efflux conjugated flavonoids out of 
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the cell more than unconjugated flavonoids, therefore reducing the 
intracellular accumulation (Williamson et al., 2007). EGC and its 
metabolites also supported the theory that conjugation reduces 
bioactivity. EGC showed a reduction of mtDNA damage by 45.3 %, 
compared to 29.5 % for 4’-O-methyl-EGC, 20.75 % for 4’-O-methyl-
EGC-glucuronide, and 12.9 % for 4’-O-methyl-EGC-sulfates. Although 
all the conjugates significantly reduced mtDNA damage, they were all 
significantly lower than the parent EGC, indicating reduced absorption 
into the intestinal cells, or increased efflux via ATP-dependant 
transporters. This is the first time to our knowledge that the bioactivities 
of 4’-O-methyl-EGC-glucuronide, 4’-O-methyl-EGC-sulfates, and ECG-
glucuronides (mixture of 2) have been reported. However, it must be 
stressed that these metabolites were not present in the experiments in 
their purified forms and future studies must elucidate the exact 
structures of these conjugates, and then purify them to use in the 
studies. This will enable their exact bioactivities to be determined without 
any hindrance from other assay components.   
Another novel aspect of this study was measuring the bioactivity in terms 
of protection against mtDNA damage of 3’-O-methyl-EC-sulfates. These 
were formed after incubation of 3’-O-methyl-EC with liver cytosol 
(chapter 4) over 210 minutes. 3’-O-methyl-EC showed significant 
bioactivity, protecting the mtDNA by 32.6 % from damage, which agreed 
with previous studies of the activity of methylated EC (Duenas et al., 
2010, Nakagawa et al., 2007). The mixture of 3’-O-methyl-EC-sulfates 
reduced mtDNA damage by 20.3 %, which was a 33.3 % reduction in 
protective capacity when compared to the parent compound. Some cells 
have the ability to deconjugate metabolites to their parent compounds, 
which might enhance their absorption and reduce their efflux, which may 
contribute to the bioactivity of these conjugates.  
In conclusion, the results presented in this chapter show that green tea 
catechins offer greater protection against mtDNA damage than their 
conjugated counterparts, although the conjugates still retain significant 
protective activities against mtDNA damage. Conjugation of catechins 
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generally reduces bioactivity, and this may be due to greater difficulty in 
entering and accumulating in cells, greater affinity for efflux transporters, 
and conjugation on the main ring to which the specific bioactivity is 
attributed to. Dietary catechins also show they have a potential new 
function – independent of their antioxidant function - of protecting 
mitochondria. These data together show that even though bioavailability 
of catechins is low in vivo, these catechins and their metabolites in small 
concentrations could synergistically protect mitochondria from external 
oxidative stressors.  
Of course more detailed studies are needed which would help to 
elucidate the exact mechanism by which catechins and their metabolites 
protect mtDNA from H2O2 induced damage. As mentioned previously, 
these experiments would have to use purified metabolites rather than 
mixtures obtained from enzyme assays.  
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Chapter 6 – Inhibition of Green tea catechin 
glucuronidation by Piperine and Quercetin-3-β-glucoside 
 
Abstract 
 
Background: Green tea catechins have shown increasing health benefits 
over the last two decades. Their extensive metabolism and low absorption 
however make their bioavailability very low in vivo. New strategies are 
needed to potentially increase the bioavailability of beneficial flavonoids. 
piperine and quercetin are known to inhibit intestinal glucuronidation. Iy 
was hypothesised that both these compounds would be efficient inhibitors 
of intestinal catechin glucuronidation. Methods: Enzyme assays were 
carried out using human intestinal microsomes as both quercetin and 
piperine showed no inhibition towards liver microsomes. Assays were run 
with and without piperine or quercetin. Samples were removed after 
certain time-points and analysed via ULC/MS. Results: Piperine and 
quercetin both significantly reduced the glucuronidation of EGC and EC.  
Glucuronidation of EGCG and ECG was also reduced, however was not 
statistically significant for all individual metabolites. Piperine was a more 
effective inhibitor than quercetin for the non-gallated catechins, and 
quercetin was more effective in the case of the gallated catechins. 
Conclusions:  This study shows that common dietary compounds which 
can inhibit certain phase II conjugation pathways may potentially increase 
the bioavailability of beneficial polyphenols in the diet. Further studies are 
needed to determine how this effect on metabolism occurs in cell lines and 
in vivo. Other dietary compounds should also be explored to potentially 
increase bioavailability of tea catechins.  
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6.1– Introduction 
 
Green tea catechins have been shown to have possible health benefits 
in numerous in vitro, animal, and human studies (Henning et al., 2011, 
Jung et al., 2001, Yang and Wang, 2010). The main catechins attributed 
to the beneficial effects of green tea are Epigallocatechin (EGC), 
Epicatechin-gallate (ECG), Epigallocatechin gallate (EGCG) (the most 
abundant, accounting for up to 50-80 % of catechins), and Epicatechin 
(EC) (Sang et al., 2011).  
The health benefits of green tea catechins are somewhat limited due to 
low bioavailability, which is due to limited absorption, extensive phase II 
metabolism, and efflux (Lambert et al., 2007). As the potential benefits 
of catechins are dependent upon the concentrations circulating in 
plasma after absorption, strategies which can improve bioavailability are 
much sought after. These strategies could include reducing efflux by 
cellular transporters, phase II conjugating enzyme inhibitors, or 
compounds which can increase cellular uptake of a target polyphenol. 
Catechins and other polyphenols, must first pass the intestinal 
epithelium, which is full of phase II enzyme containing enterocytes (Won 
et al., 2012).  Phase II metabolism occurs extensively in the liver and 
intestine, with the major pathway usually being glucuronidation in 
humans (Ritter, 2007, Wu et al., 2011). Dietary constituents and herbs 
have been shown previously to inhibit intestinal glucuronidation (Li et al., 
2012, Mohamed and Frye, 2011). Metabolites of catechins tend to have 
reduced bioactivities when compared to their parent compounds, but 
some metabolites have also demonstrated equal bioactivities to their 
parent counterparts (Cren-Olive et al., 2003, Duenas et al., 2010, Lu et 
al., 2003).  
Other methods of attempting to enhance bioavailability of polyphenols 
have tried to change the site of absorption to the small intestine, 
improving metabolic stability, and new methods of delivery (Cao et al., 
2013, Nielsen et al., 2006, Walle, 2007, Zhang et al., 2011). An easier, 
cheaper, or faster method favourably modifying the bioavailability of 
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catechins would be to consume common dietary compounds or foods 
that have been shown to inhibit intestinal or liver phase II metabolism, or 
increase absorption (Monobe et al., 2011). Piperine (figure 6.0) is an 
alkaloid and is one such compound which has been shown previously to 
inhibit glucuronidation in rats (Singh et al., 1986), and inhibit intestinal 
glucuronidation of EGCG and increase its bioavailability in mice 
(Lambert et al., 2004), however the inhibition of EGC, ECG, and EC 
glucuronidation was not analysed in this study. Quercetin (figure 6.0) is 
also a known inhibitor of Glucuronidation, more specifically a mixed-type 
inhibitor (Mohamed and Frye, 2010) and a common flavonoid in the diet; 
being present in apples, broccoli, garlic, raw onions, spinach, and red 
wine (Aherne and O'Brien, 2002).  
 
As a common dietary component, and modulator of UGT activity, the aim 
was to analyse the inhibitory effects of Quercetin on green tea catechin 
glucuronidation via intestinal and liver microsomes. 
The study of Piperine and EGCG did not mention any of the other 
catechin being analysed for inhibition of glucuronidation. And to our 
knowledge it has not been reported elsewhere. It was hypothesised that 
because Piperine inhibited EGCG glucuronidation, it could also likely 
inhibit glucuronidation of the other three major catechins.  
 
Figure 6.0 – Structures of quercetin (A) and piperine (B). Quercetin acts as a mixed-type inhibitor, and 
piperine as a non-competitive inhibitor of intestinal glucuronidation 
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6.2– Materials and methods 
 
6.2.1 – Chemicals and reagents 
 
The following were purchased from Sigma Aldrich (Gillingham, UK): 
Ascorbic Acid; Catechins (EGCG, EGC, ECG, & EC); Molecular biology 
grade H2O; Piperine; Quercetin-3-β-glucoside; and 0.5 Molar Tris-HCl 
buffer. ULC/MS-grade Acetonitrile; ULC/MS-grade methanol; Acetic acid; 
and Formic acid were purchased from Biosolve BV (Valkenswaard, the 
Netherlands). Human liver microsomes (HLM), and human intestinal 
microsomes (HIM), UGT reaction mix A (25mM UDPGA), UGT reaction 
mix B (250mM Tris-HCl buffer, 40mM MgCl2, 0.125mg/mL Alamethicin) 
were acquired from BD biosciences (Swindon, UK). The UGT-Glo™ 
assay kit was purchased from Promega (Southampton, UK) to measure 
inhibition of UGT activity.  
 
6.2.2 – UGT-Glo™ assay  
 
The UGT-Glo™ assay was used to measure the inhibitory effects of 
Quercetin and Piperine on intestinal and liver microsome glucuronidation.  
Pro-luciferin substrates were used (supplied by the assay) to measure 
UGT activity via luminescence. Varying concentrations of Piperine and 
Quercetin-3-β-glucoside (0.5 – 400 µM) were used to determine the IC50 
values of these compounds to inhibit glucuronidation.  
 
6.2.3 – Intestinal glucuronidation of Catechins and inhibition via 
Quercetin and Piperine 
 
Glucuronide assays were carried out using the manufacturer’s 
instructions (BD biosciences). Molecular biology grade H2O, UGT 
reaction mix A, UGT reaction mix B, 200 µM catechin substrate, the 
IC50 concentrations of Piperine and Quercetin-3-β-glucoside, and 50µM 
ascorbic acid were combined in a total volume of 1mL and warmed to 
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37oC for 5 minutes. The reactions were initiated using 0.2mg of Human 
intestinal microsomes HIM. Samples of 100µL were removed at 0, 10, 
20, 30, 60, 90, 120, and 180 minutes and added to 100µL of ice-cold 
methanol containing 1% ascorbic acid and acetic acid. After 
centrifugation at 10000g for 10 minutes the supernatants were analysed 
via LC/MS. The assays were repeated twice.  
 
6.2.4 – Data acquisition 
 
Analysis of catechins and their metabolites was carried out using mass 
spectrometric detection in negative ionisation electrospray mode on an 
Acquity UPLC system and Synapt-G2 HDMS (Waters, UK). Separation 
was acquired via an Xbridge C18 column (50mm x 4.6mm i.d., 3.5µm) at 
a flow rate of 0.3mL/min; and column temperature was maintained at 
35oC. The sample injection volume was 3 µL. The sampling cone voltage 
was set at 35V; desolvation temperature at 350oC; and source 
temperature at 100oC. Leucine Enkephalin (2ng/mL) was used as a 
reference compound in negative ion mode (m/z 554.2648).  The mobile 
phases were (A) 0.1% Formic acid in water (w/v) and (B) 0.1% Formic 
acid in acetonitrile. Initial conditions were 3% B for 1 minute, increasing 
to 18% B at 6 minutes, staying constant at 18% B until 6.5 minutes, back 
to 3% B at 6.6 minutes, and then stayed at 3% B until 8 minutes. 
Accurate masses were obtained using Masslynx 4.1 software, with 
scanning across the spectrum of 50-1000 m/z.  
 
6.2.5 – Data analysis  
 
All data were analysed using GraphPad Prism 5.03 (GraphPad software 
Inc. La Jolla, California). Values were expressed mean ± SD (n=2) and 
statistical significance was determined using one-way ANOVA with 
Tukey’s test. Differences were considered significant if P values were 
<0.05.  
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6.3– Results 
 
The UGT-Glo™ assay was carried out to determine if Piperine and 
Quercetin had inhibitory effects on glucuronidation in human liver and 
intestinal microsomes (figure 6.1). The IC50 of Piperine inhibition on 
intestinal glucuronidation was 106.4 µM. This was the concentration 
used in further inhibition experiments with green tea catechins. There 
was no inhibition observed with Piperine in liver microsome 
glucuronidation, even at 500 µM. The IC50 of Quercetin-3-β-glucoside 
inhibition of intestine microsome glucuronidation was 15.2 µM. As seen 
with Piperine, there was no inhibition of glucuronidation observed in liver 
microsomes.  
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Figure 6.1 – Incubation of various concentrations of Piperine and Quercetin with human 
intestinal microsomes in the UGT-Glo assay to determine their inhibitory effects against 
intestinal glucuronidation. The data was analysed using GraphPad prism to obtain IC50 
values for both compounds; 15.2 µM for Quercetin and 106.4 µM for Piperine. Values 
are expressed as the mean ± SD (n = 3). Incubation time in the UGT-glo assay was as 
instructed in the UGT-glo assay protocol (Promega). 
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Inhibition of EGCG glucuronidation 
 
The results in chapter 4 showed that catechins were efficiently 
conjugated by UGT enzymes in human liver and intestinal microsomes. 
For this reason glucuronidation was chosen as the metabolism pathway 
in the in vitro systems to test for inhibition via common food compounds. 
However, as there was no inhibition observed via liver microsomes, the 
focus was instead on intestinal inhibition of glucuronide formation.  
 
After incubation of EGCG with intestinal microsomes, three glucuronides 
were produced (chapter 4, figure 4.4).Piperine was shown to significantly 
reduce glucuronide conjugation of only one EGCG glucuronide (G5, 
chapter 4, figure 4.4) when incubated with intestinal microsomes.  
Figure 6.2 shows the reduction in EGCG glucuronide formation in the 
presence of 106.4 µM Piperine. Each experiment was repeated in 
duplicate. Although there were visible differences in the conjugation of 
EGCG as shown with the individual concentrations of glucuronides, the 
only significant reduction was in the formation of glucuronide 1 (G5, 
figure 4.4 in chapter 4) (figure 6.2).  Piperine inhibited total glucuronide 
conjugation by approximately 42.8 %, 48.1 %, 43.7 %, and 27.2 % at 10, 
20, 30, and 60 minutes, respectively. Figure 6.3 shows the reduction in 
EGCG glucuronide formation in the presence of 15.2 µM Quercetin-3-β-
glucoside. Glucuronide conjugation was inhibited by 58.9 %, 62.1 %, 
61.4 %, and 42.1 % at 10, 20, 30, and 60 minutes respectively. 
In the case of EGCG, Quercetin-3-β-glucoside showed a higher inhibitory 
effect than Piperine on glucuronide formation at all time-points; 16.1 % at 
10 minutes, 14 % at 20 minutes, 17.7 % at 30 minutes, and 14.9 % at 60 
minutes. 
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Figure 6.2 – EGCG glucuronidation with intestinal microsomes in the presence of 
Piperine. Formation of all three glucuronide conjugates was reduced; however, only the 
first glucuronide (glucuronide 1 - top left) showed significant inhibition by Piperine at 20 
and 30 minutes. The combined glucuronides are also shown but did not show 
statistically significant inhibition of EGCG glucuronide production (bottom right). Values 
are expressed as the mean ± SD (n = 2). *P < 0.05.  
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Inhibition of EGC glucuronidation 
 
After incubation of EGC with intestinal microsomes, two glucuronides 
were produced (chapter 4, figure 4.8). Both glucuronides were produced 
in relatively low amounts compared to ECG and EGCG glucuronides. 
One glucuronide reached a peak concentration of 5.03 µM, and the 
second minor glucuronide conjugate reached 1.22 µM at 90 minutes. 
When EGC was incubated in the presence of Piperine and Quercetin-3-
β-glucoside, the formation of the minor glucuronide (G9, figure 4.8) was 
not affected. The results for the glucuronide (G8) which was inhibited by 
both compounds are shown in figure 6.4. The inhibitory effects of both 
Piperine and Quercetin on G8 were similar up to 30 minutes, at which 
point the difference in inhibition became clearer, Piperine being the 
superior inhibitor up to 90 minutes. Piperine inhibited EGC-glucuronide 1 
Figure 6.3 – EGCG glucuronidation with intestinal microsomes in the presence of 
Quercetin-3-β-glucoside. Formation of all three glucuronide conjugates was reduced; 
however, only 2 glucuronides (glucuronides 1 and 2 - top) showed significant inhibition 
at 10, 20, and 30 minutes. The combined glucuronides are also shown and had 
significantly increased inhibition of EGCG glucuronide production at 20 and 30 minutes 
(bottom right). Values are expressed as the mean ± SD (n = 2). *P < 0.05. 
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(G8) conjugation by 72.1 %, 77.6 %, 75.1 %, 78.9 %, and 76.9 % at 10, 
20, 30, 60, and 90 minutes respectively. At the same time points Quercetin 
inhibited glucuronidation of (G8) EGC by 74.6 %, 75.1 %, 69.9 %, 55.5 %, 
and 42.4 %.  
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Inhibition of EC glucuronidation 
 
Figure 6.5 shows the results of co-incubation of EC with Piperine and 
Quercetin. The inhibition followed the same pattern as EGC, in the 
sense that Piperine was the more efficient inhibitor of EC 
glucuronidation than Quercetin at their respective IC50 concentrations. 
The results of the glucuronide shown were the major glucuronide (G15, 
figure 4.16) formed with EC and intestinal microsome incubation. Both 
Piperine and Quercetin had no inhibitory effect on the conjugation of the 
second, minor EC glucuronide (G16, figure 4.16). Piperine reduced EC 
glucuronide formation by statistically significant 78.1, 74.4, 78.2, 73.8, 
Figure 6.4 – EGC glucuronidation with intestinal microsomes in the presence of 
Quercetin-3-β-glucoside and Piperine. Formation of the main glucuronide conjugate 
was reduced significantly as established via one way ANOVA with Tukey’s test; 
Piperine inhibited the glucuronide formation signif icantly at all time-points, and 
Quercetin-3-β-glucoside showed statistically significant inhibition up to 60 minutes. 
Values are expressed as the mean ± SD (n = 2). *P < 0.05. 
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and 66.4 % at 30, 60, 90, 120, and 180 minutes respectively. With 
Quercetin, the reduction in glucuronide conjugation was only calculated 
as significant at 60, 90, and 180 minutes where the inhibition was 51.4 
%, 52.6 %, and 46.6 % respectively. Although not deemed significant 
statistically, there were still distinct reductions in glucuronide formation 
at 30 and 120 minutes, where the inhibition was calculated as 35.3 % 
and 44.5 % respectively.  
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Inhibition of ECG glucuronidation 
 
Four glucuronides were produced after incubation of ECG with intestinal 
microsomes (figure 4.15, chapter 4). The combined concentration of the 
glucuronides reached approximately 83 % after 180 minutes. The main 
glucuronide (G11) reached a maximum concentration of 53.34 µM, and 
the other three metabolites reached 7.2 (G12), 12.3 (G13), and 9.6 µM 
Figure 6.5 – EC glucuronidation with intestinal microsomes in the presence of 
Quercetin-3-β-glucoside and Piperine. Formation of the main glucuronide conjugate 
was reduced significantly as established via one way ANOVA with Tukey’s test; 
Piperine inhibited the glucuronide formation significantly at all time-points, and 
Quercetin-3-β-glucoside showed statistically significant inhibition at 60, 90, and 180 
minutes. Values are expressed as the mean ± SD (n = 2). *P < 0.05. 
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(G14) after 180 minutes.  Figure 6.6 shows the results of co-incubation 
of ECG with Piperine and Quercetin. Piperine was shown to be less 
effective than Quercetin at inhibiting glucuronidation of ECG for the 
three minor metabolites, however, had a visibly greater impact on 
glucuronidation for the major ECG glucuronide (glucuronide 4 in figure 
6.6, G11 in figure 4.15).  
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Figure 6.6 – ECG glucuronidation with intestinal microsomes in the presence of 
Quercetin-3-β-glucoside and Piperine. Values are expressed as the mean ± SD (n = 2). 
*P < 0.05, ** < 0.01. 
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6.4 – Discussion 
 
In this study, the aim was to determine the inhibitory effects of two common 
dietary compounds, Quercetin and Piperine on glucuronidation using human 
microsomes.  In previous studies, Piperine demonstrated inhibition of 
glucuronidation by inhibiting gastrointestinal transit of solids/liquids in rats 
and mice, inhibition of 3-hydroxybenzo(a) pyrene glucuronidation, and also 
significantly increased the bioavailability of curcumin (Bajad et al., 2001, 
Shoba et al., 1998, Singh et al., 1986). Lambert et al showed that EGCG 
glucuronidation was significantly inhibited by Piperine, and that it increased 
bioavailability in mice (Lambert et al., 2004). Quercetin had also previously 
shown to have inhibitory effects on both intestinal and liver microsomal 
glucuronidation (Mohamed and Frye, 2010) with IC50 values of 5.8 and 19.1 
µM respectively. Based on these findings, it was hypothesised that EGCG, 
EGC, ECG, and EC glucuronidation would also be significantly inhibited by 
Piperine and Quercetin.  
Glucuronidation by liver microsomes was not observed in the UGT-Glo 
assay with neither Quercetin nor Piperine. However, both compounds 
significantly inhibited glucuronidation via intestinal microsomes. This finding 
was probably due to differing UGT isoforms present in the two microsomal 
fractions, UGT1A8 and UGT1A10 being the intestine-specific isoforms 
(Tukey and Strassburg, 2000).  
EGCG was co incubated with intestinal microsomes in the presence of 
106.4 µM Piperine and showed a reduction in glucuronidation of between 
27.2 % and 48.1 %. However, these values were not statistically significant 
as calculated by a one way ANOVA combined with Tukey’s test, potentially 
due to the fact that the experiment was only carried out in duplicate. 
However, the results agree with the study carried out by Lambert et al, 
which showed a 40 % inhibition of glucuronidation of EGCG when co 
incubated with 100 µM Piperine (Lambert et al., 2004). Following this, the 
assay was carried out with Quercetin (15.2 µM) as it had also shown 
significant inhibition of intestinal glucuronidation the UGT-Glo assay. Co-
incubation with Quercetin resulted in statistically significant inhibitory effects 
on EGCG glucuronide formation at 20 and 30 minutes of 42.1 % and 62.1 % 
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respectively. Although not statistically significant from one another, 
Quercetin offered a greater UGT inhibitory effect than Piperine on EGCG 
glucuronide formation. This was most likely due to direct competition, as 
Quercetin has a similar structure to catechins, and a glucuronide of 
Quercetin was also detected in the assay via LC/MS. It must be stressed 
that the Quercetin added to the enzyme assays was in its glucoside form 
(Quercetin-3-β-glucoside), which is generally how it appears in dietary 
sources, and this is not to be mistaken with Quercetin-glucuronide which 
was the UGT mediated conjugate detected after incubation with intestinal 
microsomes.  
The results from these two compounds with EGCG suggest that inhibition of 
intestinal EGCG glucuronidation can potentially increase plasma 
concentrations of EGCG. Inhibition of glucuronidation can be more distinct 
in the case of Quercetin where there is competition for UGT enzymes, and 
enzyme co-factors such as UDP-glucuronic acid. Whereas Piperine 
mediated glucuronide inhibition of EGCG was compensated for by 
increased methylation of EGCG in HT-29 cells (Lambert et al., 2004). This 
wouldn’t affect the bioavailability as there would still be very similar 
concentrations of metabolites formed and therefore in the plasma.  
Similar results were observed with ECG. Quercetin appeared to have a 
greater inhibitory effect on glucuronidation on three glucuronides; however, 
the major glucuronide had a greater inhibition with Piperine over the 180 
minutes of the assay. Over the first 20 minutes, Quercetin was visibly better 
at inhibiting glucuronide formation than Piperine. However Piperine became 
the major inhibitor at 60 minutes up until the end of the assay. This could be 
explained by the degradation of Quercetin over the assay period. However, 
Quercetin could have been extensively glucuronidated in the assay, as was 
seen with the formation of a Quercetin-glucuronide, which in turn had a 
lesser inhibitory effect on glucuronidation of the catechins.  
EGC and EC in contrast to EGCG and ECG demonstrated that Piperine had 
a greater inhibitory effect on their respective glucuronide formation. Both 
had two glucuronides each in the UGT assay with intestinal microsomes but 
only one showed glucuronidation inhibition with Piperine and Quercetin. 
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This may be explained by the fact that they were present in very small 
concentrations compared to the major glucuronide product of EGC and EC. 
Interestingly, both EGC and EC showed statistically significant reductions in 
glucuronide conjugation. Piperine reduced glucuronidation of EGC by 72.1 
– 78.9 %, and Quercetin 42.4 – 75.1 %. EC glucuronidation was inhibited by 
66.4 – 78.2 %, and Quercetin inhibited glucuronide formation by 35.3 – 52.6 
%. The difference in glucuronidation inhibition by Piperine and Quercetin 
towards the gallated and non-gallated catechins was unexpected. As the 
gallated catechins were used first in the experiments, it was assumed that 
the non-gallated catechins would also follow the inhibition properties 
demonstrated by Piperine and Quercetin; the non-gallated catechins are 
more extensively conjugated in vivo, hence would be more susceptible to 
inhibitory effects of other compounds. The use of intestinal microsomes in 
this study, and not intact cells also allowed us to determine that the 
inhibition was via direct actions on the UGT enzymes and not via uptake / 
efflux cellular transporters. 
The results in our study demonstrate that common dietary compounds co-
administered can decrease metabolism of green tea catechins significantly. 
This can potentially increase the bioavailability of the more bioactive parent 
catechins to circulate in the plasma and exert their beneficial health effects. 
The increase may be primarily due to inhibition of glucuronidation, and not 
necessarily due to increases in absorption. In the case of both Quercetin 
and Piperine it would be worthwhile to carry out detailed studies in cell 
systems also to see exactly which components are affected by the inhibitory 
compounds. And indeed the same should be done for other common food 
ingredients that are consumed regularly by the general population, so they 
can also be investigated for their potential health benefits, either via direct 
health effects, or by inhibiting the metabolism of beneficial polyphenols/ 
compounds in the diet.  
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Chapter 7 – General discussion and future directions 
  
7.1 – Summary of thesis findings 
The aim of this thesis was to determine the absorption and potential 
health effects of green tea catechins in the oral cavity, metabolism of 
catechins in different enzyme fractions, protective effects of catechins 
and their metabolites against H2O2 induced mitochondrial DNA damage 
in intestinal cells, and inhibition of catechin metabolism by common food 
ingredients.  
The key findings from chapter 3 were that green tea significantly 
reduced intracellular ROS levels in human oral cells, all four main 
catechins were significantly absorbed in human H400 oral cell lines, and 
all four catechins had significant protective effects against mtDNA 
damage in oral H400 cells. 
The results from chapter 4 showed that green tea catechins were not 
significantly sulfated using liver s9 and cytosolic fractions, and that 
glucuronidation using intestinal and liver fractions showed the highest 
metabolism in our experimental systems. Methylation via porcine COMT 
significantly metabolised EGCG and EGC, and to a smaller extent EC. 
No methylated metabolites of ECG were detected. Methylation of EGCG 
at the 4’ position (4’O-methyl-EGCG) greatly enhanced its glucuronidation 
via human liver microsomes. This was also the case for 4’-O-methyl-EGC 
where methylation at the 4’ position greatly increased glucuronidation via 
liver microsomes, and sulfation via human liver cytosol.  When EC was 
methylated at the 3’ position, its capacity for sulfate conjugation greatly 
increased.  
The key findings in chapter 5 showed that incubating physiological 
concentrations of catechins with intestinal cells for 4 hours conferred 
significant protection against H2O2 induced mtDNA damage. Metabolites 
of catechins showed reduced bioactivity but still significantly protected 
mtDNA against H2O2 induced damage. 
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In chapter 6 it was demonstrated that Piperine and Quercetin both 
significantly reduced the glucuronidation of EGC and EC. 
Glucuronidation of EGCG and ECG was also visibly reduced, however 
was not statistically significant for all individual metabolites. Piperine was 
a more effective inhibitor than Quercetin for the non-gallated catechins, 
and Quercetin was more effective in the case of the gallated catechins. 
 
 
7.2 – Absorption and health effects in the oral cavity 
In this study the effects of green tea catechins on protection against 
mitochondrial DNA damage were analysed, and to what extent catechins 
were absorbed into oral cells. Human H400 oral cell lines and buccal 
mucosal cells from human volunteers were used. The results showed 
extensive absorption of catechins in the oral cells after incubation with 
catechins for up to 60 minutes. EGCG and ECG were more extensively 
absorbed than EGC and EC, although the latter both were also absorbed 
in significant amounts. This was in agreement with previous studies 
which indicated high concentrations of catechins present in the saliva of 
subjects consuming 2-3 cups of green tea (Yang et al., 1999), and 
chewing green tea leaves (Lee et al., 2004). Both these studies however 
did not measure uptake of catechins in the oral cells, which was the 
novel approach in our experiments. Such uptake of catechins in oral 
cells led us to conclude that there is significant antioxidant protection 
against other potentially harmful compounds such as carcinogens from 
smoking or environmental pollution. The results from the mtDNA assay 
showed significant reductions in H2O2 induced damage in H400 cells, 
which indicated that the absorbed catechins are present in sufficient 
concentrations to prevent damage to mitochondria in the oral cavity. This 
agreed with previous studies which also showed positive effects of green 
tea catechins in the oral cavity (Zhang and Kashket, 1998, Yamamoto et 
al., 2003, Tsao et al., 2009, Maruyama et al., 2011, Magalhaes et al., 
2009, Hirasawa et al., 2006, Ferrazzano et al., 2011), however these 
studies also did not measure intracellular levels of catechins in the oral 
mucosa. The concentrations used for the absorption studies and mtDNA 
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assays reflect the physiological concentration ranges that can be 
obtained from 2 – 3 cups of green tea. The oral mucosa is a good model 
system to study for its potential health benefits when exposed to 
catechins because it is one of the very few areas of the GI tract which is 
directly exposed to high concentrations of intact polyphenols in a 
physiological manner. It is worth noting that there were no conjugated 
metabolites observed in our experiments in oral cells. This was expected 
as there are no reported phase II enzymes expressed in the oral 
mucosa. The results from the study taken together indicate a potential 
role for beneficial health effects in the oral cavity; however the 
mechanisms of action at the molecular level still need to be studied 
further. Of course more in depth studies must be carried out in order to 
determine the exact in vivo situation occurring, which would help to 
ascertain exactly what concentrations of catechins are present inside the 
buccal cells and not just in the saliva. Another good avenue to explore 
would be to determine if catechins are actually adsorbed onto buccal 
cells in humans, as this would give a good starting point to the designing 
of strategies to have a constant stream of catechins being delivered to 
the oral cavity and GI tract, which could be in the form or sweets, 
beverages, or chewing gum. 
7.3 – Protective effects of catechins and their metabolites against 
H2O2 induced mtDNA damage 
Polyphenols are extensively metabolised via the action of phase II 
enzymes when ingested, and these metabolites have been shown to 
retain some bioactivity, albeit decreased when compared to their parent 
compounds. (Zhu et al., 2000, Lambert et al., 2007). The aim of this 
study was two-fold; to determine the activity of catechins and their 
metabolites, and protection against H2O2 induced mitochondrial DNA 
damage in intestinal cells. This is because mtDNA is more susceptible to 
ROS induced damage than nuclear DNA, and has less efficient repair 
mechanisms in place (Tulah and Birch-Machin, 2013, Alexeyev, 2009). 
Intestinal cells like oral cells are exposed to high concentrations of intact 
flavonoids after ingestion, however there is also extensive conjugation 
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which takes place in the small intestine (Walle et al., 1999, 
Vaidyanathan and Walle, 2002, Spencer, 2003, Hu et al., 2003). It was 
hypothesised, based on the studies in the oral cavity, that catechins 
would also significantly protect intestinal cells against mtDNA damage, 
and that if the metabolites showed any protective effects; they would be 
lower than the parent compounds. The results showed that physiological 
concentrations of catechins significantly protected mtDNA against 
damage in these cells. There was one instance when comparing the 
effectiveness of a parent catechin against its metabolite (EGCG vs 4’-
methyl-EGCG), where the metabolite showed a slightly greater 
bioactivity, although this was not statistically significant. The rest of the 
catechins and their metabolites showed the expected outcomes of 
reduced bioactivity with conjugation (chapter 5). It is important to note 
here that although the intestine is exposed to high levels of flavonoids, 
their absorption is low (Walle et al., 1999, Walgren et al., 2000, 
Vaidyanathan and Walle, 2003, Vaidyanathan and Walle, 2001, Chan et 
al., 2007), which is why lower concentrations were used in this study. A 
major improvement in understanding the biological effects of catechins 
in intestinal cells is required. For this, future research would need to 
ascertain exact uptake concentrations of the targets flavonoid, and 
elucidate exact mechanisms by which they and their metabolites act to 
protect cells against mtDNA damage at physiological concentrations. 
Another avenue which will greatly improve our understanding of the 
bioactivities of metabolites would be the use of purified metabolites, 
which exact structures also known. This has important implications for 
the maintenance of good GI tract health, as there is potential for 
oxidative damage from environmental and ingested toxins in the 
intestinal epithelium. The studies can be further extended to other 
tissues which are constantly under oxidative stress, and can assess the 
protective effects, if any, against mtDNA damage. And as higher 
concentrations of catechins are required for antioxidant activities, it is 
unlikely that the protective effects are solely due to their direct ROS 
scavenging actions. What is more likely however, is the activation of 
some signalling pathways which allow the target tissues/cells to increase 
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the expression of innate cellular defences. This is of course needs to be 
studied in depth to elucidate exact mechanisms and signalling pathways 
affected.   
7.4 – Inhibition of glucuronidation of catechins by Piperine and 
Quercetin 
A previous study carried out by Lambert et al showed that bioavailability 
and metabolism of EGCG was favourably altered when co-administered 
with the purine alkaloid Piperine (Lambert et al., 2004). They did not 
however report on any differences in bioavailability and metabolism of 
the other three major catechins found in green tea. Our results were in 
agreement in regards to Piperine only inhibiting intestinal 
glucuronidation of EGCG and not liver glucuronidation. It was shown in 
this study for the first time that Piperine (106.4 µM) also reduced the 
metabolism of EGC and EC significantly over 90 and 180 minutes 
respectively. Although the results showed visibly distinct reductions in 
metabolism of ECG in the presence of Piperine, this was not deemed 
statistically significant.  
Another known dietary inhibitor of glucuronidation was also tested for its 
ability to inhibit catechin metabolism in liver and intestinal microsomes. 
Consistent with the results obtained with Piperine, Quercetin also 
selectively inhibited intestinal glucuronidation and had no effect on liver 
microsome metabolism. Our results showed that Quercetin was also 
efficient at inhibiting the metabolism of catechins, albeit at a much lower 
concentration (15.2 µM) than Piperine. Quercetin was more effective 
than Piperine in reducing EGCG glucuronidation, possibly due to the fact 
that it directly competed with the catechin for the UGT active sites, being 
a flavonoid itself. This was confirmed with the detection of a Quercetin-
glucuronide in all catechin incubations. In contrast, Piperine was shown 
to be a better inhibitor of EGC and EC glucuronidation than Quercetin. In 
the case of ECG, two of its metabolites showed less glucuronidation in 
the presence of Quercetin, one in the presence of Piperine, and one was 
reduced approximately the same. The results from this study indicate 
that less expensive and complicated strategies can be used to enhance 
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bioavailability of catechins. This is in contrast to strategies which aim to 
modify catechins before ingestion, encapsulation in various food 
matrices, and the use of nano-particle based delivery systems (Yao et 
al., 2015, Zhang et al., 2011). Further studies should also determine 
whether or not other common food ingredients can inhibit metabolism of 
target flavonoids, and if they have the same effects in vivo. This would 
greatly enhance our understanding of synergistic effects of polyphenols 
consumption in humans.  
7.5 – Conclusions 
The results from our studies provide a potential role of green tea 
catechins for maintaining good oral and intestinal health. They can act 
as preliminary studies in the preparation of more detailed and rigorous 
experiments which will help our understanding of polyphenol interactions 
with cells and other compounds, to determine precise mechanisms of 
action and cellular targets, and establish exact concentrations which can 
reach target tissues/cells. Future studies should use more 
physiologically representative catechins, i.e., conjugated catechins 
which are present in vivo and at precise concentrations that they are 
present in a particular target tissue, this will give a more comprehensive 
understanding of the potential effects of catechins in humans. Another 
relevant avenue of exploration is the precise effects on colon tissues as 
significant amounts of catechins pass through the intestine where they 
reach the colon and undergo metabolism via the colonic microflora, 
which are also important in determining exact biological effects of tea 
catechins.  
Of course one of the limitations of our study was that purified 
metabolites were not used in some experiments, and future studies 
should take this into account, especially when trying to extrapolate in 
vitro results with in vivo health effects. This would greatly aid in 
translating the biological effects in vitro with a mechanistic 
understanding of target tissues in vivo.  
Another limitation to overcome in future studies whether in vitro or in 
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vivo would be to design longer-term and better defined studies, which 
can incorporate the true effect of chronic, physiologically relevant 
exposure to catechins.  
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